
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/base_style-CPPDhfna.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-BepKMsUl.js"></script>

  <link rel="stylesheet" href="/static/assets/article_style-DUfI1jZp.css" />
<link rel="stylesheet" href="/static/assets/style-BOrsu84o.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-D3wJHomh.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="18DE2367930AE133002367004758CDEA.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="jamasd">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11822619/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="JAMA Psychiatry">
<meta name="citation_title" content="Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial">
<meta name="citation_author" content="Christian S Hendershot">
<meta name="citation_author_institution" content="Department of Population and Public Health Sciences and Institute for Addiction Science, Keck School of Medicine, University of Southern California, Los Angeles">
<meta name="citation_author_institution" content="Department of Psychiatry, University of North Carolina at Chapel Hill">
<meta name="citation_author_institution" content="Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill">
<meta name="citation_author" content="Michael P Bremmer">
<meta name="citation_author_institution" content="Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill">
<meta name="citation_author_institution" content="Department of Psychiatry and Neuroscience, University of North Carolina at Chapel Hill">
<meta name="citation_author" content="Michael B Paladino">
<meta name="citation_author_institution" content="Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill">
<meta name="citation_author_institution" content="Department of Psychiatry and Neuroscience, University of North Carolina at Chapel Hill">
<meta name="citation_author" content="Georgios Kostantinis">
<meta name="citation_author_institution" content="Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill">
<meta name="citation_author" content="Thomas A Gilmore">
<meta name="citation_author_institution" content="Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill">
<meta name="citation_author" content="Neil R Sullivan">
<meta name="citation_author_institution" content="Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill">
<meta name="citation_author" content="Amanda C Tow">
<meta name="citation_author_institution" content="Department of Psychiatry, University of North Carolina at Chapel Hill">
<meta name="citation_author" content="Sarah S Dermody">
<meta name="citation_author_institution" content="Department of Psychology, Toronto Metropolitan University, Toronto, Ontario, Canada">
<meta name="citation_author" content="Mark A Prince">
<meta name="citation_author_institution" content="Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles">
<meta name="citation_author" content="Robyn Jordan">
<meta name="citation_author_institution" content="Department of Psychiatry, University of North Carolina at Chapel Hill">
<meta name="citation_author" content="Sherry A McKee">
<meta name="citation_author_institution" content="Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut">
<meta name="citation_author" content="Paul J Fletcher">
<meta name="citation_author_institution" content="Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada">
<meta name="citation_author_institution" content="Department of Psychology, University of Toronto, Toronto, Ontario, Canada">
<meta name="citation_author_institution" content="Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada">
<meta name="citation_author" content="Eric D Claus">
<meta name="citation_author_institution" content="Department of Biobehavioral Health, The Pennsylvania State University, University Park">
<meta name="citation_author" content="Klara R Klein">
<meta name="citation_author_institution" content="Department of Medicine, University of North Carolina School of Medicine, Chapel Hill">
<meta name="citation_publication_date" content="2025 Feb 12">
<meta name="citation_volume" content="82">
<meta name="citation_issue" content="4">
<meta name="citation_firstpage" content="395">
<meta name="citation_doi" content="10.1001/jamapsychiatry.2024.4789">
<meta name="citation_pmid" content="39937469">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11822619/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11822619/">
<meta name="description" content="Does the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide reduce alcohol consumption and craving in adults with alcohol use disorder (AUD)? In this randomized clinical trial, relative to placebo, low-dose semaglutide reduced the amount ...">
<meta name="og:title" content="Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Does the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide reduce alcohol consumption and craving in adults with alcohol use disorder (AUD)? In this randomized clinical trial, relative to placebo, low-dose semaglutide reduced the amount ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11822619/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="11822619">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1001/jamapsychiatry.2024.4789"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11822619%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/11822619/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/11822619/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11822619/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-jamasd.png" alt="JAMA Network logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to JAMA Network" title="Link to JAMA Network" shape="default" href="https://doi.org/10.1001/jamapsychiatry.2024.4789" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">JAMA Psychiatry</button></div>. 2025 Feb 12;82(4):395–405. doi: <a href="https://doi.org/10.1001/jamapsychiatry.2024.4789" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1001/jamapsychiatry.2024.4789</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22JAMA%20Psychiatry%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22JAMA%20Psychiatry%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22JAMA%20Psychiatry%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22JAMA%20Psychiatry%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Once-Weekly Semaglutide in Adults With Alcohol Use Disorder</h1>
<p>A Randomized Clinical Trial</p></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hendershot%20CS%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Christian S Hendershot</span></a><div hidden="hidden" id="id1">
<h3>
<span class="name western">Christian S Hendershot</span>, <span class="degrees">PhD</span>
</h3>
<div class="p">
<sup>1</sup>Department of Population and Public Health Sciences and Institute for Addiction Science, Keck School of Medicine, University of Southern California, Los Angeles</div>
<div class="p">
<sup>2</sup>Department of Psychiatry, University of North Carolina at Chapel Hill</div>
<div class="p">
<sup>3</sup>Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hendershot%20CS%22%5BAuthor%5D" class="usa-link"><span class="name western">Christian S Hendershot</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>3,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bremmer%20MP%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Michael P Bremmer</span></a><div hidden="hidden" id="id2">
<h3>
<span class="name western">Michael P Bremmer</span>, <span class="degrees">MA</span>
</h3>
<div class="p">
<sup>3</sup>Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill</div>
<div class="p">
<sup>4</sup>Department of Psychiatry and Neuroscience, University of North Carolina at Chapel Hill</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bremmer%20MP%22%5BAuthor%5D" class="usa-link"><span class="name western">Michael P Bremmer</span></a>
</div>
</div>
<sup>3,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Paladino%20MB%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Michael B Paladino</span></a><div hidden="hidden" id="id3">
<h3>
<span class="name western">Michael B Paladino</span>, <span class="degrees">BS</span>
</h3>
<div class="p">
<sup>3</sup>Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill</div>
<div class="p">
<sup>4</sup>Department of Psychiatry and Neuroscience, University of North Carolina at Chapel Hill</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Paladino%20MB%22%5BAuthor%5D" class="usa-link"><span class="name western">Michael B Paladino</span></a>
</div>
</div>
<sup>3,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kostantinis%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Georgios Kostantinis</span></a><div hidden="hidden" id="id4">
<h3>
<span class="name western">Georgios Kostantinis</span>, <span class="degrees">BA</span>
</h3>
<div class="p">
<sup>3</sup>Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kostantinis%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Georgios Kostantinis</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gilmore%20TA%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Thomas A Gilmore</span></a><div hidden="hidden" id="id5">
<h3>
<span class="name western">Thomas A Gilmore</span>, <span class="degrees">BA</span>
</h3>
<div class="p">
<sup>3</sup>Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gilmore%20TA%22%5BAuthor%5D" class="usa-link"><span class="name western">Thomas A Gilmore</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sullivan%20NR%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Neil R Sullivan</span></a><div hidden="hidden" id="id6">
<h3>
<span class="name western">Neil R Sullivan</span>, <span class="degrees">BA</span>
</h3>
<div class="p">
<sup>3</sup>Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sullivan%20NR%22%5BAuthor%5D" class="usa-link"><span class="name western">Neil R Sullivan</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tow%20AC%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Amanda C Tow</span></a><div hidden="hidden" id="id7">
<h3>
<span class="name western">Amanda C Tow</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>2</sup>Department of Psychiatry, University of North Carolina at Chapel Hill</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tow%20AC%22%5BAuthor%5D" class="usa-link"><span class="name western">Amanda C Tow</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dermody%20SS%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Sarah S Dermody</span></a><div hidden="hidden" id="id8">
<h3>
<span class="name western">Sarah S Dermody</span>, <span class="degrees">PhD, CPsych</span>
</h3>
<div class="p">
<sup>5</sup>Department of Psychology, Toronto Metropolitan University, Toronto, Ontario, Canada</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dermody%20SS%22%5BAuthor%5D" class="usa-link"><span class="name western">Sarah S Dermody</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Prince%20MA%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Mark A Prince</span></a><div hidden="hidden" id="id9">
<h3>
<span class="name western">Mark A Prince</span>, <span class="degrees">PhD</span>
</h3>
<div class="p">
<sup>6</sup>Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Prince%20MA%22%5BAuthor%5D" class="usa-link"><span class="name western">Mark A Prince</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jordan%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Robyn Jordan</span></a><div hidden="hidden" id="id10">
<h3>
<span class="name western">Robyn Jordan</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>2</sup>Department of Psychiatry, University of North Carolina at Chapel Hill</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jordan%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Robyn Jordan</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22McKee%20SA%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Sherry A McKee</span></a><div hidden="hidden" id="id11">
<h3>
<span class="name western">Sherry A McKee</span>, <span class="degrees">PhD</span>
</h3>
<div class="p">
<sup>7</sup>Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22McKee%20SA%22%5BAuthor%5D" class="usa-link"><span class="name western">Sherry A McKee</span></a>
</div>
</div>
<sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fletcher%20PJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Paul J Fletcher</span></a><div hidden="hidden" id="id12">
<h3>
<span class="name western">Paul J Fletcher</span>, <span class="degrees">PhD</span>
</h3>
<div class="p">
<sup>8</sup>Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</div>
<div class="p">
<sup>9</sup>Department of Psychology, University of Toronto, Toronto, Ontario, Canada</div>
<div class="p">
<sup>10</sup>Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fletcher%20PJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Paul J Fletcher</span></a>
</div>
</div>
<sup>8,</sup><sup>9,</sup><sup>10</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Claus%20ED%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Eric D Claus</span></a><div hidden="hidden" id="id13">
<h3>
<span class="name western">Eric D Claus</span>, <span class="degrees">PhD</span>
</h3>
<div class="p">
<sup>11</sup>Department of Biobehavioral Health, The Pennsylvania State University, University Park</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Claus%20ED%22%5BAuthor%5D" class="usa-link"><span class="name western">Eric D Claus</span></a>
</div>
</div>
<sup>11</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Klein%20KR%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Klara R Klein</span></a><div hidden="hidden" id="id14">
<h3>
<span class="name western">Klara R Klein</span>, <span class="degrees">MD, PhD</span>
</h3>
<div class="p">
<sup>12</sup>Department of Medicine, University of North Carolina School of Medicine, Chapel Hill</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Klein%20KR%22%5BAuthor%5D" class="usa-link"><span class="name western">Klara R Klein</span></a>
</div>
</div>
<sup>12</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="yoi240094aff1">
<sup>1</sup>Department of Population and Public Health Sciences and Institute for Addiction Science, Keck School of Medicine, University of Southern California, Los Angeles</div>
<div id="yoi240094aff2">
<sup>2</sup>Department of Psychiatry, University of North Carolina at Chapel Hill</div>
<div id="yoi240094aff3">
<sup>3</sup>Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill</div>
<div id="yoi240094aff4">
<sup>4</sup>Department of Psychiatry and Neuroscience, University of North Carolina at Chapel Hill</div>
<div id="yoi240094aff5">
<sup>5</sup>Department of Psychology, Toronto Metropolitan University, Toronto, Ontario, Canada</div>
<div id="yoi240094aff6">
<sup>6</sup>Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles</div>
<div id="yoi240094aff7">
<sup>7</sup>Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut</div>
<div id="yoi240094aff8">
<sup>8</sup>Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</div>
<div id="yoi240094aff9">
<sup>9</sup>Department of Psychology, University of Toronto, Toronto, Ontario, Canada</div>
<div id="yoi240094aff10">
<sup>10</sup>Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada</div>
<div id="yoi240094aff11">
<sup>11</sup>Department of Biobehavioral Health, The Pennsylvania State University, University Park</div>
<div id="yoi240094aff12">
<sup>12</sup>Department of Medicine, University of North Carolina School of Medicine, Chapel Hill</div>
<div class="author-notes p">
<div class="fn" id="p1">
<p><strong>Accepted for Publication:</strong> November 27, 2024.</p>
<p><strong>Published Online:</strong> February 12, 2025. doi:<a href="https://doi.org/10.1001/jamapsychiatry.2024.4789" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1001/jamapsychiatry.2024.4789</a></p>
<p><strong>Open Access:</strong> This is an open access article distributed under the terms of the <a href="https://jamanetwork.com/pages/cc-by-license-permissions" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">CC-BY License</a>. © 2025 Hendershot CS et al. <em>JAMA Psychiatry</em>.</p>
</div>
<div class="fn" id="yoi240094cor1">
<sup>✉</sup><p class="display-inline"><strong>Corresponding Author:</strong> Christian S. Hendershot, PhD, Department of Population and Public Health Sciences and Institute for Addiction Science, Keck School of Medicine, University of Southern California, 1845 N Soto St, Ste 201, Los Angeles, CA 90032 (<span>christian.hendershot@usc.edu</span>).</p>
</div>
<div class="fn" id="p4">
<p><strong>Author Contributions:</strong> Dr Hendershot and Mr Bremmer had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p>
<p><em>Concept and design</em>: Hendershot, Kostantinis, Tow, Dermody, Jordan, McKee, Fletcher, Claus, Klein.</p>
<p><em>Acquisition, analysis, or interpretation of data</em>: Hendershot, Bremmer, Paladino, Kostantinis, Gilmore, Sullivan, Tow, Dermody, Prince, McKee, Klein.</p>
<p><em>Drafting of the manuscript</em>: Hendershot, Paladino, Kostantinis, Sullivan, Dermody, Prince, Klein.</p>
<p><em>Critical review of the manuscript for important intellectual content</em>: Hendershot, Bremmer, Paladino, Gilmore, Sullivan, Tow, Dermody, Prince, Jordan, McKee, Fletcher, Claus, Klein.</p>
<p><em>Statistical analysis</em>: Hendershot, Bremmer, Paladino, Kostantinis, Sullivan, Dermody, Prince.</p>
<p><em>Obtained funding</em>: Hendershot, Dermody, Claus.</p>
<p><em>Administrative, technical, or material support</em>: Hendershot, Kostantinis, Gilmore, Sullivan, Tow, McKee, Klein.</p>
<p><em>Supervision</em>: Hendershot, Jordan.</p>
<p><strong>Conflict of Interest Disclosures:</strong> Dr Klein reported consulting fees from Novo Nordisk outside the submitted work and is supported by the University of North Carolina Department of Medicine Physician Scientist Training Program, University of North Carolina School of Medicine Physician Scientist Training Program, and the National Center for Advancing Translational Sciences, National Institutes of Health; additionally, Dr Klein has received research related contracts (paid to institution) from Bayer, Boehringer-Ingelheim, Carmot, Diasome, Eli Lilly, Novo Nordisk, Rhythm Pharmaceuticals, and vTv Therapeutics. No other disclosures were reported.</p>
<p><strong>Funding/Support:</strong> This research was supported by National Institute on Alcohol Abuse and Alcoholism grant R21AA026931. The project received support from the National Center for Advancing Translational Sciences through grant award number UM1TR004406. Dr Hendershot acknowledges support from the Department of Psychiatry and Bowles Center for Alcohol Studies, University of North Carolina Chapel Hill School of Medicine.</p>
<p><strong>Role of the Funder/Sponsor:</strong> The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p>
<p><strong>Disclaimer:</strong> The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p>
<p><strong>Meeting Presentation:</strong> Preliminary results from this study were presented at the 2024 College of Problems on Drug Dependence Annual Scientific Meeting; June 16, 2024, Montreal, Quebec; the 2024 Research Society on Alcohol Annual Scientific Meeting; June 24, 2024, Minneapolis, Minnesota; the 2024 ISBRA/APSAAR World Congress on Alcohol and Addictions; September 25, 2024, Melbourne, Australia; and the 2024 NIDA-National Institute on Alcohol Abuse and Alcoholism Frontiers in Addiction Research Mini-Convention; October, 4, 2024, Chicago, Illinois.</p>
<p><strong>Data Sharing Statement:</strong> See <a href="#note-YOI240094-1-s" class="usa-link">Supplement 3</a>.</p>
<p><strong>Additional Contributions:</strong> The study team thanks John Buse, MD, PhD, UNC-Chapel Hill, for project consultation; Alex Kass, MSN, MBA, RN, UNC-Chapel Hill, and the clinical research staff at the University of North Carolina Endocrinology, Diabetes, and Obesity Clinical Research Unit for assistance with study coordination and medication procedures; Ethan Campbell, BS, UNC-Chapel Hill; Amisha Garikipati, BS, UNC-Chapel Hill; and Lily Al-Omari, BS, UNC-Chapel Hill, for assistance with data collection; and Mengshan Zhang, UNC-Chapel Hill, and Andrew Jenkins, PhD, UNC-Chapel Hill, for assistance with data management. Dr Hendershot thanks Katie Witkiewitz, PhD, University of New Mexico, Matthew Maciejewski, PhD, Duke University, Lorenzo Leggio, MD, PhD, National Institutes of Health, and Anders Fink-Jensen, MD, DMSci, University of Copenhagen, for their feedback on an earlier draft of this article. No compensation was provided.</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2024 Aug 16; Accepted 2024 Nov 27; Issue date 2025 Apr.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>Copyright 2025 Hendershot CS et al. <em>JAMA Psychiatry</em>.</div>
<p>This is an open access article distributed under the terms of the CC-BY License.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC11822619  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39937469/" class="usa-link">39937469</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Key Points</h2>
<section id="ab-yoi240094-1"><h3 class="pmc_sec_title">Question</h3>
<p>Does the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide reduce alcohol consumption and craving in adults with alcohol use disorder (AUD)?</p></section><section id="ab-yoi240094-2"><h3 class="pmc_sec_title">Findings</h3>
<p>In this randomized clinical trial, relative to placebo, low-dose semaglutide reduced the amount of alcohol consumed during a posttreatment laboratory self-administration procedure. Over 9 weeks of treatment, semaglutide led to reductions in some but not all measures of weekly consumption, significantly reduced weekly alcohol craving relative to placebo, and led to greater relative reductions in cigarettes per day in a subgroup of participants with current cigarette use.</p></section><section id="ab-yoi240094-3"><h3 class="pmc_sec_title">Meaning</h3>
<p>These results justify larger clinical trials of incretin therapies for AUD.</p></section></section><section class="abstract" id="abstract2"><hr class="headless">
<p>This randomized clinical trial assesses the effects of subcutaneous semaglutide on alcohol consumption in adults with alcohol use disorder.</p></section><section class="abstract" id="abstract3"><h2>Abstract</h2>
<section id="ab-yoi240094-4"><h3 class="pmc_sec_title">Importance</h3>
<p>Preclinical, observational, and pharmacoepidemiology evidence indicates that glucagon-like peptide 1 receptor agonists (GLP-1RAs) may reduce alcohol intake. Randomized trials are needed to determine the clinical significance of these findings.</p></section><section id="ab-yoi240094-5"><h3 class="pmc_sec_title">Objective</h3>
<p>To evaluate the effects of once-weekly subcutaneous semaglutide on alcohol consumption and craving in adults with alcohol use disorder (AUD).</p></section><section id="ab-yoi240094-6"><h3 class="pmc_sec_title">Design, Setting, and Participants</h3>
<p>This was a phase 2, double-blind, randomized, parallel-arm trial involving 9 weeks of outpatient treatment. Enrollment occurred at an academic medical center in the US from September 2022 to February 2024. Of 504 potential participants assessed, 48 non–treatment-seeking participants with AUD were randomized.</p></section><section id="ab-yoi240094-7"><h3 class="pmc_sec_title">Intervention</h3>
<p>Participants received semaglutide (0.25 mg/week for 4 weeks, 0.5 mg/week for 4 weeks, and 1.0 mg for 1 week) or placebo at weekly clinic visits.</p></section><section id="ab-yoi240094-8"><h3 class="pmc_sec_title">Main Outcomes and Measures</h3>
<p>The primary outcome was laboratory alcohol self-administration, measured at pretreatment and posttreatment (0.5 mg/week). Secondary and exploratory outcomes, including prospective changes in alcohol consumption and craving, were assessed at outpatient visits.</p></section><section id="ab-yoi240094-9"><h3 class="pmc_sec_title">Results</h3>
<p>Forty-eight participants (34 [71%] female; mean [SD] age, 39.9 [10.6] years) were randomized. Low-dose semaglutide reduced the amount of alcohol consumed during a posttreatment laboratory self-administration task, with evidence of medium to large effect sizes for grams of alcohol consumed (β, −0.48; 95% CI, −0.85 to −0.11; <em>P</em> = .01) and peak breath alcohol concentration (β, −0.46; 95% CI, −0.87 to −0.06; <em>P</em> = .03). Semaglutide treatment did not affect average drinks per calendar day or number of drinking days, but significantly reduced drinks per drinking day (β, −0.41; 95% CI, −0.73 to −0.09; <em>P</em> = .04) and weekly alcohol craving (β, −0.39; 95% CI, −0.73 to −0.06; <em>P</em> = .01), also predicting greater reductions in heavy drinking over time relative to placebo (β, 0.84; 95% CI, 0.71 to 0.99; <em>P</em> = .04). A significant treatment-by-time interaction indicated that semaglutide treatment predicted greater relative reductions in cigarettes per day in a subsample of individuals with current cigarette use (β, −0.10; 95% CI, −0.16 to −0.03; <em>P</em> = .005).</p></section><section id="ab-yoi240094-10"><h3 class="pmc_sec_title">Conclusions and Relevance</h3>
<p>These findings provide initial prospective evidence that low-dose semaglutide can reduce craving and some drinking outcomes, justifying larger clinical trials to evaluate GLP-1RAs for alcohol use disorder.</p></section><section id="ab-yoi240094-11"><h3 class="pmc_sec_title">Trial Registration</h3>
<p>ClinicalTrials.gov Identifier: <a href="https://clinicaltrials.gov/study/NCT05520775?tab=results" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05520775</a></p></section></section><section id="H1-1-YOI240094"><h2 class="pmc_sec_title">Introduction</h2>
<p>Alcohol use is a leading modifiable cause of morbidity and mortality, accounting for an estimated 4% to 5% of disease burden and 2.6 million deaths per year globally.<sup><a href="#yoi240094r1" class="usa-link" aria-describedby="yoi240094r1">1</a>,<a href="#yoi240094r2" class="usa-link" aria-describedby="yoi240094r2">2</a></sup> Alcohol is causally linked to more than 200 medical and disability conditions,<sup><a href="#yoi240094r2" class="usa-link" aria-describedby="yoi240094r2">2</a></sup> with increased risks of common diseases (including cardiovascular disease, liver disease, and cancers) accounting for a large proportion of alcohol-related morbidity.<sup><a href="#yoi240094r1" class="usa-link" aria-describedby="yoi240094r1">1</a>,<a href="#yoi240094r3" class="usa-link" aria-describedby="yoi240094r3">3</a>,<a href="#yoi240094r4" class="usa-link" aria-describedby="yoi240094r4">4</a></sup> Increased incidence of alcohol-related liver disease since 2020 has contributed to a 29% increase in alcohol-related mortality in the US since 2016-2017.<sup><a href="#yoi240094r3" class="usa-link" aria-describedby="yoi240094r3">3</a>,<a href="#yoi240094r5" class="usa-link" aria-describedby="yoi240094r5">5</a>,<a href="#yoi240094r6" class="usa-link" aria-describedby="yoi240094r6">6</a></sup> An estimated 178 000 US deaths per year are alcohol attributable,<sup><a href="#yoi240094r3" class="usa-link" aria-describedby="yoi240094r3">3</a></sup> with further increases in rates of alcohol-related disease projected.<sup><a href="#yoi240094r4" class="usa-link" aria-describedby="yoi240094r4">4</a>,<a href="#yoi240094r7" class="usa-link" aria-describedby="yoi240094r7">7</a>,<a href="#yoi240094r8" class="usa-link" aria-describedby="yoi240094r8">8</a></sup></p>
<p>While roughly 29% and 11% of US adults meet lifetime and past-year criteria for alcohol use disorder (AUD), respectively,<sup><a href="#yoi240094r9" class="usa-link" aria-describedby="yoi240094r9">9</a>,<a href="#yoi240094r10" class="usa-link" aria-describedby="yoi240094r10">10</a></sup> less than 10% of those with AUD report past-year treatment<sup><a href="#yoi240094r10" class="usa-link" aria-describedby="yoi240094r10">10</a></sup> and less than 2% receive pharmacotherapy,<sup><a href="#yoi240094r11" class="usa-link" aria-describedby="yoi240094r11">11</a></sup> defining one of the largest known health care treatment gaps.<sup><a href="#yoi240094r12" class="usa-link" aria-describedby="yoi240094r12">12</a></sup> Underutilization of AUD medications is attributed to multiple factors, including few Food and Drug Administration (FDA)–approved therapies, limited awareness of these medications, and barriers related to stigma.<sup><a href="#yoi240094r12" class="usa-link" aria-describedby="yoi240094r12">12</a>,<a href="#yoi240094r13" class="usa-link" aria-describedby="yoi240094r13">13</a></sup> Reduced alcohol intake, irrespective of abstinence, is associated with improved health outcomes.<sup><a href="#yoi240094r14" class="usa-link" aria-describedby="yoi240094r14">14</a>,<a href="#yoi240094r15" class="usa-link" aria-describedby="yoi240094r15">15</a>,<a href="#yoi240094r16" class="usa-link" aria-describedby="yoi240094r16">16</a></sup> Medications that facilitate reductions in alcohol use while achieving broad clinical uptake would fill a critical unmet need.</p>
<p>Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs) are incretin mimetic therapies with exceptional efficacy for the treatment of diabetes and obesity.<sup><a href="#yoi240094r17" class="usa-link" aria-describedby="yoi240094r17">17</a>,<a href="#yoi240094r18" class="usa-link" aria-describedby="yoi240094r18">18</a>,<a href="#yoi240094r19" class="usa-link" aria-describedby="yoi240094r19">19</a></sup> Semaglutide, a long-acting GLP-1RA with superior efficacy to older GLP-1RA medications, received FDA approval for diabetes in 2017 and obesity in 2021.<sup><a href="#yoi240094r20" class="usa-link" aria-describedby="yoi240094r20">20</a></sup> Rapidly increasing prescription rates have been accompanied by reports of reductions in alcohol use and craving during treatment.<sup><a href="#yoi240094r21" class="usa-link" aria-describedby="yoi240094r21">21</a>,<a href="#yoi240094r22" class="usa-link" aria-describedby="yoi240094r22">22</a></sup> These observations were predated by substantial preclinical evidence that GLP-1RAs reduce voluntary alcohol consumption and attenuate alcohol reinforcement,<sup><a href="#yoi240094r23" class="usa-link" aria-describedby="yoi240094r23">23</a>,<a href="#yoi240094r24" class="usa-link" aria-describedby="yoi240094r24">24</a>,<a href="#yoi240094r25" class="usa-link" aria-describedby="yoi240094r25">25</a>,<a href="#yoi240094r26" class="usa-link" aria-describedby="yoi240094r26">26</a></sup> suggesting potential clinical applications of GLP-1RAs for AUD.<sup><a href="#yoi240094r26" class="usa-link" aria-describedby="yoi240094r26">26</a>,<a href="#yoi240094r27" class="usa-link" aria-describedby="yoi240094r27">27</a>,<a href="#yoi240094r28" class="usa-link" aria-describedby="yoi240094r28">28</a>,<a href="#yoi240094r29" class="usa-link" aria-describedby="yoi240094r29">29</a></sup> Although experimental evidence for semaglutide-related reductions in alcohol intake remains specific to nonhuman studies,<sup><a href="#yoi240094r30" class="usa-link" aria-describedby="yoi240094r30">30</a>,<a href="#yoi240094r31" class="usa-link" aria-describedby="yoi240094r31">31</a>,<a href="#yoi240094r32" class="usa-link" aria-describedby="yoi240094r32">32</a>,<a href="#yoi240094r33" class="usa-link" aria-describedby="yoi240094r33">33</a></sup> off-label prescribing for AUD is already reported, necessitating clinical trials.<sup><a href="#yoi240094r21" class="usa-link" aria-describedby="yoi240094r21">21</a>,<a href="#yoi240094r34" class="usa-link" aria-describedby="yoi240094r34">34</a></sup> This prospective phase 2 randomized clinical trial evaluated the effects of once-weekly subcutaneous semaglutide in non–treatment-seeking adults with AUD.</p></section><section id="H1-2-YOI240094"><h2 class="pmc_sec_title">Methods</h2>
<section id="H2-1-YOI240094"><h3 class="pmc_sec_title">Trial Design</h3>
<p>This phase 2 clinical trial used a hybrid design, combining clinical outpatient and human laboratory components, to evaluate the effects of semaglutide in non–treatment-seeking adults with AUD. The outpatient sequence involved 9 weeks of medication or placebo (weeks 1-9) and a final assessment visit (week 10). Objective laboratory alcohol self-administration was assessed at pretreatment (prior to week 1) and between weeks 8 and 9 (at 0.5 mg/week). Other outcomes were assessed prospectively at weekly clinic visits. This investigator-initiated trial was conducted at the University of North Carolina (UNC)–Chapel Hill School of Medicine with oversight from the UNC institutional review board and under an investigational new drug exemption granted by the FDA. The trial protocol is in <a href="#note-YOI240094-1-s" class="usa-link">Supplement 1</a>. All participants provided written informed consent.</p></section><section id="H2-2-YOI240094"><h3 class="pmc_sec_title">Participant Sample</h3>
<p>Non–treatment-seeking adults with AUD were recruited via online and public advertisements. Primary inclusion criteria included age 21 to 65 years, reporting past-year <em>DSM-5</em> criteria for AUD, past-month endorsement of more than 7 (women) or more than 14 (men) standard drinks in a week with 2 or more heavy drinking episodes (4 or more drinks for women and 5 or more for men), and ability to attend weekly clinic visits and pretreatment and posttreatment laboratory sessions. Key exclusion criteria included currently seeking treatment for alcohol problems or actively attempting to reduce consumption; past use of GLP-1 receptor agonists; weight loss medications; body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) less than 23; past-year substance use disorder other than AUD, tobacco use disorder, or mild cannabis use disorder; recent (30-day) use of illicit drugs except cannabis; history of diabetes, and current medical or neurological illness precluding participation based on physician judgement. See the eMethods in <a href="#note-YOI240094-1-s" class="usa-link">Supplement 2</a> for full eligibility criteria. Enrollment lasted from September 2022 to February 2024.</p></section><section id="H2-3-YOI240094"><h3 class="pmc_sec_title">Study Procedures</h3>
<p>Following written informed consent and eligibility confirmation, participants completed a pretreatment alcohol self-administration session before the week 1 medication visit. Participants then completed 8 additional medication or placebo visits (weeks 2-9), a posttreatment alcohol self-administration session (scheduled between weeks 8 and 9), and a discharge visit (week 10, no medication). See the eMethods in <a href="#note-YOI240094-1-s" class="usa-link">Supplement 2</a> for additional procedural details.</p></section><section id="H2-4-YOI240094"><h3 class="pmc_sec_title">Intervention</h3>
<p>Subcutaneous semaglutide was administered according to standard practice, with dose increases every 4 weeks. To maximize safety and feasibility, only the 2 lowest dose sequences (0.25 mg/week for weeks 1-4 and 0.5 mg/week for weeks 5-8) were used prior to primary outcome collection (between weeks 8 and 9). To obtain additional safety and prospective data, participants received a final dose increase (1.0 mg) at week 9, contingent on tolerability. The week 9 dose was treated as flexible and could be held at 0.5 mg or deferred for safety or practical reasons, based on physician judgement. Participants, investigators, and outcome assessors were blind to condition (see the eMethods in <a href="#note-YOI240094-1-s" class="usa-link">Supplement 2</a> for additional placebo and blinding information).</p></section><section id="H2-5-YOI240094"><h3 class="pmc_sec_title">Outcomes Assessment</h3>
<section id="H3-1-YOI240094"><h4 class="pmc_sec_title">Laboratory Alcohol Self-Administration</h4>
<p>Objective self-administration (the primary outcome) was assessed by embedding human laboratory procedures in the trial design. Prior work supports the sensitivity of laboratory self-administration to detect pharmacotherapy effects.<sup><a href="#yoi240094r35" class="usa-link" aria-describedby="yoi240094r35">35</a>,<a href="#yoi240094r36" class="usa-link" aria-describedby="yoi240094r36">36</a></sup> A standardized procedure<sup><a href="#yoi240094r37" class="usa-link" aria-describedby="yoi240094r37">37</a></sup> was used to estimate voluntary alcohol consumption and ability to delay drinking. Participants were presented with their preferred beverage and brand and could elect to delay drinking for up to 50 minutes for monetary reinforcement. Thereafter, participants were instructed to consume at their preferred pace to achieve preferred effects over 120 minutes.<sup><a href="#yoi240094r37" class="usa-link" aria-describedby="yoi240094r37">37</a></sup> The available alcohol amount (in grams) was determined with anthropometric formulas based on a prespecified maximum breath alcohol concentration (BrAC) limit. BrAC was measured every 30 minutes after drinking onset. Estimated volume consumed (g-ETOH) and peak BrAC served as co–primary outcome measures. See the eMethods in <a href="#note-YOI240094-1-s" class="usa-link">Supplement 2</a> for additional details.</p></section><section id="H3-2-YOI240094"><h4 class="pmc_sec_title">Weekly Consumption and Craving</h4>
<p>Weekly consumption was assessed using calendar-based methods<sup><a href="#yoi240094r38" class="usa-link" aria-describedby="yoi240094r38">38</a></sup> supplemented with daily logs to facilitate recall. Outcomes included average drinks per calendar day (registered secondary outcome), with additional quantity and frequency outcomes common to AUD trials (drinks per drinking day, number of heavy drinking days, number of drinking vs abstinent days), and weekly craving<sup><a href="#yoi240094r39" class="usa-link" aria-describedby="yoi240094r39">39</a></sup> examined as exploratory and hypothesis-generating outcomes. The proportion of participants with zero heavy drinking days served as an exploratory outcome relevant to FDA end points.<sup><a href="#yoi240094r40" class="usa-link" aria-describedby="yoi240094r40">40</a></sup> Cigarettes per day (registered secondary outcome) was assessed during calendar-based assessments.<sup><a href="#yoi240094r38" class="usa-link" aria-describedby="yoi240094r38">38</a></sup> See the eMethods in <a href="#note-YOI240094-1-s" class="usa-link">Supplement 2</a> for additional information.</p></section><section id="H3-3-YOI240094"><h4 class="pmc_sec_title">Additional Clinical and Safety Outcomes</h4>
<p>Body weight and systolic and diastolic blood pressure were assessed weekly. Side effects, adverse events, and depression symptoms were queried weekly using standardized instruments.<sup><a href="#yoi240094r41" class="usa-link" aria-describedby="yoi240094r41">41</a>,<a href="#yoi240094r42" class="usa-link" aria-describedby="yoi240094r42">42</a></sup></p></section></section><section id="H2-6-YOI240094"><h3 class="pmc_sec_title">Statistical Analyses</h3>
<p>Power analyses informed a target sample of 48 randomized participants (see the eMethods in <a href="#note-YOI240094-1-s" class="usa-link">Supplement 2</a> for rationale and full analysis plan). Primary, secondary, and exploratory outcomes were evaluated with linear mixed models and full information maximum likelihood estimation to accommodate missing data (lme4 package version 35.5;<sup><a href="#yoi240094r43" class="usa-link" aria-describedby="yoi240094r43">43</a></sup> RStudio version 2024.04.2 + 764 [R Foundation]).</p>
<p>Models of weekly outcomes used intention-to-treat principles (all 48 randomized participants included). Primary intention-to-treat analyses of laboratory outcomes consisted of residualized change models testing medication effects on posttreatment self-administration (g-ETOH and peak BrAC; session 2) controlling for pretreatment levels (session 1). These models estimated medication effects on quantitative consumption during self-administration. Some participants elected not to engage in alcohol consumption, resulting in the presence of missing data for g-ETOH and peak BrAC. Thus, those who opted not to engage in the task contributed data to the intention-to-treat analyses for weekly drinking outcomes and non–self-administration laboratory outcomes (eg, delay time), but were modeled as having missing data for analyses of g-ETOH and peak BrAC, resulting in a sample of 25 with complete data for residualized change analyses. An exploratory model also tested mean BrAC across the session (see the eMethods in <a href="#note-YOI240094-1-s" class="usa-link">Supplement 2</a> for full details and rationale for statistical models).</p>
<p>Intention-to-treat linear mixed models of weekly outcomes included a random effect for participant, a fixed effect of time (study week, within-subject factor), medication group (semaglutide vs placebo, the primary effect of interest), treatment-by-time interaction, and covariates (see the eMethods in <a href="#note-YOI240094-1-s" class="usa-link">Supplement 2</a> for full model details). A preplanned linear mixed model examining cigarettes per day (registered secondary outcome) was limited to those participants reporting cigarette smoking at baseline (n = 13; 7 in the placebo group and 6 in the semaglutide group), with restricted maximum likelihood estimation given the small sample size.</p>
<p>Because preliminary estimates of effect size are needed to inform future trials of GLP-1RAs, medication effect size estimates are reported in all models (β for linear mixed models and residualized change models; small effect: β = 0.10, medium: β = 0.30, large: β = 0.50). To compare effect sizes over the 2 dosage periods, Cohen <em>d</em> values computed for the monthly intervals corresponding with dosage (0.25 mg/week in weeks 1-4 and 0.5 mg/week in weeks 5-8) are presented for descriptive purposes, using percentage change from baseline to facilitate interpretation across outcomes. Cohen <em>d</em> (small effect: <em>d</em> = 0.20, medium: <em>d</em> = 0.50; large: <em>d</em> = 0.80) was computed in the R <em>lsr</em> package version 0.5.2.</p></section></section><section id="H1-3-YOI240094"><h2 class="pmc_sec_title">Results</h2>
<section id="H2-7-YOI240094"><h3 class="pmc_sec_title">Sample Description and Retention</h3>
<p>Of the 48 participants randomized, 34 (71%) were female and 14 (29%) were male. The mean (SD) age was 39.9 (10.6) years. Most had BMI greater than 30 (n = 27) or 25.0-29.9 (n = 20); 1 participant had BMI less than 24.9. On average, participants endorsed moderate AUD severity (<a href="#yoi240094t1" class="usa-link">Table</a>). <a href="#yoi240094f1" class="usa-link">Figure 1</a> presents the CONSORT diagram. Overall, 42 of 48 participants completed outpatient visits through week 9. All participants who completed posttreatment alcohol sessions received the required 4 doses at 0.5 mg/week. See the eResults in <a href="#note-YOI240094-1-s" class="usa-link">Supplement 2</a> for full retention details.</p>
<section class="tw xbox font-sm" id="yoi240094t1"><h4 class="obj_head">Table.  Pretreatment Characteristics by Treatment Group for All Randomized Participants.</h4>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col width="44.96%" span="1">
<col width="17.98%" span="1">
<col width="19.08%" span="1">
<col width="17.98%" span="1">
<thead>
<tr>
<th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th>
<th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">Mean (SD)</th>
</tr>
<tr>
<th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Placebo</th>
<th valign="top" align="left" scope="col" rowspan="1" colspan="1">Semaglutide</th>
<th valign="top" align="left" scope="col" rowspan="1" colspan="1">Total</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1">Randomized, No.</td>
<td valign="top" align="left" rowspan="1" colspan="1">24</td>
<td valign="top" align="left" rowspan="1" colspan="1">24</td>
<td valign="top" align="left" rowspan="1" colspan="1">48</td>
</tr>
<tr>
<td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex, No.(%)</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td>
<td valign="top" align="left" rowspan="1" colspan="1">17 (71)</td>
<td valign="top" align="left" rowspan="1" colspan="1">17 (71)</td>
<td valign="top" align="left" rowspan="1" colspan="1">34 (71)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td>
<td valign="top" align="left" rowspan="1" colspan="1">7 (29)</td>
<td valign="top" align="left" rowspan="1" colspan="1">7 (29)</td>
<td valign="top" align="left" rowspan="1" colspan="1">14 (29)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, y</td>
<td valign="top" align="left" rowspan="1" colspan="1">39.0 (10.9)</td>
<td valign="top" align="left" rowspan="1" colspan="1">40.6 (10.5)</td>
<td valign="top" align="left" rowspan="1" colspan="1">39.9 (10.6)</td>
</tr>
<tr>
<td valign="top" align="left" scope="col" rowspan="1" colspan="1">Race, No.(%)<a href="#yoi240094t1n1" class="usa-link"><sup>a</sup></a>
</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Asian</td>
<td valign="top" align="left" rowspan="1" colspan="1">2 (8)</td>
<td valign="top" align="left" rowspan="1" colspan="1">0</td>
<td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Black/African American</td>
<td valign="top" align="left" rowspan="1" colspan="1">4 (17)</td>
<td valign="top" align="left" rowspan="1" colspan="1">3 (13)</td>
<td valign="top" align="left" rowspan="1" colspan="1">7 (15)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hawaiian/Pacific Islander</td>
<td valign="top" align="left" rowspan="1" colspan="1">0</td>
<td valign="top" align="left" rowspan="1" colspan="1">0</td>
<td valign="top" align="left" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> White</td>
<td valign="top" align="left" rowspan="1" colspan="1">18 (75)</td>
<td valign="top" align="left" rowspan="1" colspan="1">21 (88)</td>
<td valign="top" align="left" rowspan="1" colspan="1">39 (81)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other (unspecified) or multiple</td>
<td valign="top" align="left" rowspan="1" colspan="1">0</td>
<td valign="top" align="left" rowspan="1" colspan="1">0</td>
<td valign="top" align="left" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hispanic ethnicity, No.(%)<a href="#yoi240094t1n1" class="usa-link"><sup>a</sup></a>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">2 (8)</td>
<td valign="top" align="left" rowspan="1" colspan="1">2 (8)</td>
<td valign="top" align="left" rowspan="1" colspan="1">4 (8)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1">AUD symptoms, <em>DSM-5</em>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">4.3 (2.0)</td>
<td valign="top" align="left" rowspan="1" colspan="1">4.1 (1.5)</td>
<td valign="top" align="left" rowspan="1" colspan="1">4.2 (1.7)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1">AUDIT</td>
<td valign="top" align="left" rowspan="1" colspan="1">14.2 (6.5)</td>
<td valign="top" align="left" rowspan="1" colspan="1">12.7 (5.6)</td>
<td valign="top" align="left" rowspan="1" colspan="1">13.4 (6.0)</td>
</tr>
<tr>
<td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Alcohol consumption<a href="#yoi240094t1n2" class="usa-link"><sup>b</sup></a>
</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Drinks/calendar day</td>
<td valign="top" align="left" rowspan="1" colspan="1">3.0 (1.7)</td>
<td valign="top" align="left" rowspan="1" colspan="1">2.7 (1.7)</td>
<td valign="top" align="left" rowspan="1" colspan="1">2.9 (1.7)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Drinks/drinking day</td>
<td valign="top" align="left" rowspan="1" colspan="1">4.5 (2.5)</td>
<td valign="top" align="left" rowspan="1" colspan="1">3.8 (1.8)</td>
<td valign="top" align="left" rowspan="1" colspan="1">4.2 (2.2)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Drinking days</td>
<td valign="top" align="left" rowspan="1" colspan="1">19.6 (5.5)</td>
<td valign="top" align="left" rowspan="1" colspan="1">20.8 (6.8)</td>
<td valign="top" align="left" rowspan="1" colspan="1">20.2 (6.1)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Heavy drinking days</td>
<td valign="top" align="left" rowspan="1" colspan="1">9.8 (5.5)</td>
<td valign="top" align="left" rowspan="1" colspan="1">8.4 (7.9)</td>
<td valign="top" align="left" rowspan="1" colspan="1">9.1 (6.8)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Alcohol craving, PACS score</td>
<td valign="top" align="left" rowspan="1" colspan="1">12.2 (6.5)</td>
<td valign="top" align="left" rowspan="1" colspan="1">11.9 (4.7)</td>
<td valign="top" align="left" rowspan="1" colspan="1">12.0 (5.6)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1">Current smoking, No.(%)<a href="#yoi240094t1n3" class="usa-link"><sup>c</sup></a>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">7 (29)</td>
<td valign="top" align="left" rowspan="1" colspan="1">6 (25)</td>
<td valign="top" align="left" rowspan="1" colspan="1">13 (27)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cigarettes per day</td>
<td valign="top" align="left" rowspan="1" colspan="1">14.0 (13.5)</td>
<td valign="top" align="left" rowspan="1" colspan="1">8.0 (7.7)</td>
<td valign="top" align="left" rowspan="1" colspan="1">11.2 (11.2)</td>
</tr>
<tr>
<td valign="top" align="left" scope="col" rowspan="1" colspan="1">WHO risk level, No.(%)<a href="#yoi240094t1n4" class="usa-link"><sup>d</sup></a>
</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1</td>
<td valign="top" align="left" rowspan="1" colspan="1">5 (21)</td>
<td valign="top" align="left" rowspan="1" colspan="1">8 (33)</td>
<td valign="top" align="left" rowspan="1" colspan="1">13 (27)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2</td>
<td valign="top" align="left" rowspan="1" colspan="1">10 (42)</td>
<td valign="top" align="left" rowspan="1" colspan="1">10 (42)</td>
<td valign="top" align="left" rowspan="1" colspan="1">20 (42)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 3</td>
<td valign="top" align="left" rowspan="1" colspan="1">7 (29)</td>
<td valign="top" align="left" rowspan="1" colspan="1">4 (17)</td>
<td valign="top" align="left" rowspan="1" colspan="1">11 (23)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 4</td>
<td valign="top" align="left" rowspan="1" colspan="1">2 (8)</td>
<td valign="top" align="left" rowspan="1" colspan="1">2 (8)</td>
<td valign="top" align="left" rowspan="1" colspan="1">4 (8)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1">Weight, kg</td>
<td valign="top" align="left" rowspan="1" colspan="1">93.1 (15.1)</td>
<td valign="top" align="left" rowspan="1" colspan="1">95.4 (20.9)</td>
<td valign="top" align="left" rowspan="1" colspan="1">94.2 (18.1)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1">BMI</td>
<td valign="top" align="left" rowspan="1" colspan="1">31.7 (4.5)</td>
<td valign="top" align="left" rowspan="1" colspan="1">32.4 (6.7)</td>
<td valign="top" align="left" rowspan="1" colspan="1">32.1 (5.6)</td>
</tr>
<tr>
<td valign="top" align="left" scope="col" rowspan="1" colspan="1">BMI category, No.(%)</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> BMI &lt;30 male</td>
<td valign="top" align="left" rowspan="1" colspan="1">5 (21)</td>
<td valign="top" align="left" rowspan="1" colspan="1">4 (17)</td>
<td valign="top" align="left" rowspan="1" colspan="1">9 (19)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> BMI &lt;30 female</td>
<td valign="top" align="left" rowspan="1" colspan="1">4 (17)</td>
<td valign="top" align="left" rowspan="1" colspan="1">8 (33)</td>
<td valign="top" align="left" rowspan="1" colspan="1">12 (25)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> BMI ≥30 male</td>
<td valign="top" align="left" rowspan="1" colspan="1">2 (8)</td>
<td valign="top" align="left" rowspan="1" colspan="1">3 (13)</td>
<td valign="top" align="left" rowspan="1" colspan="1">5 (10)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> BMI ≥30 female</td>
<td valign="top" align="left" rowspan="1" colspan="1">13 (54)</td>
<td valign="top" align="left" rowspan="1" colspan="1">9 (38)</td>
<td valign="top" align="left" rowspan="1" colspan="1">22 (46)</td>
</tr>
<tr>
<td valign="top" align="left" scope="col" rowspan="1" colspan="1">Blood pressure</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Systolic</td>
<td valign="top" align="left" rowspan="1" colspan="1">127.9 (18.7)</td>
<td valign="top" align="left" rowspan="1" colspan="1">125.1 (16.2)</td>
<td valign="top" align="left" rowspan="1" colspan="1">126.5 (17.3)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Diastolic</td>
<td valign="top" align="left" rowspan="1" colspan="1">85.7 (14.7)</td>
<td valign="top" align="left" rowspan="1" colspan="1">83.7 (10.6)</td>
<td valign="top" align="left" rowspan="1" colspan="1">84.7 (12.7)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Heart rate</td>
<td valign="top" align="left" rowspan="1" colspan="1">78.8 (14.1)</td>
<td valign="top" align="left" rowspan="1" colspan="1">75.0 (10.7)</td>
<td valign="top" align="left" rowspan="1" colspan="1">76.9 (12.6)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1">HbA<sub>1C</sub>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">5.16 (0.35)</td>
<td valign="top" align="left" rowspan="1" colspan="1">5.09 (0.38)</td>
<td valign="top" align="left" rowspan="1" colspan="1">5.13 (0.36)</td>
</tr>
<tr>
<td valign="top" align="left" scope="row" rowspan="1" colspan="1">Depression (CES-D score)</td>
<td valign="top" align="left" rowspan="1" colspan="1">11.7 (10.0)</td>
<td valign="top" align="left" rowspan="1" colspan="1">12.7 (7.4)</td>
<td valign="top" align="left" rowspan="1" colspan="1">12.2 (8.7)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/yoi240094t1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="_fn_p47"><p>Abbreviations: AUD, alcohol use disorder; AUDIT, Alcohol Use Disorders Identification Test; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CES-D, Center for Epidemiologic Studies Depression Scale; HbA<sub>1c</sub>, hemoglobin A1C; PACS, Penn Alcohol Craving Scale; WHO, World Health Organization.</p></div>
<div class="fn" id="yoi240094t1n1">
<sup>
<sup>a</sup>
</sup><p class="display-inline">Race and ethnicity were collected via self-report for purposes of characterizing the sample.</p>
</div>
<div class="fn" id="yoi240094t1n2">
<sup>
<sup>b</sup>
</sup><p class="display-inline">Alcohol consumption during the 28-day period before baseline visit.</p>
</div>
<div class="fn" id="yoi240094t1n3">
<sup>
<sup>c</sup>
</sup><p class="display-inline">Defined as participants who smoked at least 1 cigarette per week during the 28-day baseline period.</p>
</div>
<div class="fn" id="yoi240094t1n4">
<sup>
<sup>d</sup>
</sup><p class="display-inline">WHO risk-level criteria are determined by sex-specific criteria for baseline reported alcohol consumption per week: level 1 = &lt;40 g for male individuals and &lt;20 g for female individuals; level 2 = 40-60 g for male individuals and 20-40 g for female individuals; level 3 = 60-100 g for male individuals and 40-60 g for female individuals; and level 4 = &gt;100 g for male individuals and &gt;60 g for female individuals.</p>
</div>
</div></section><figure class="fig xbox font-sm" id="yoi240094f1"><h4 class="obj_head">Figure 1.  CONSORT Flow Diagram.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11822619_jamapsychiatry-e244789-g001.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7b/11822619/e73696ec4ede/jamapsychiatry-e244789-g001.jpg" loading="lazy" height="1103" width="783" alt="Figure 1. "></a></p>
<div class="p text-right font-secondary"><a href="figure/yoi240094f1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure></section><section id="H2-8-YOI240094"><h3 class="pmc_sec_title">Laboratory Alcohol Self-Administration</h3>
<p>Results of residualized change models indicated that semaglutide reduced posttreatment laboratory consumption with a medium to large effect size for grams of alcohol consumed (β, −0.48; 95% CI, −0.85 to −0.11; <em>P</em> = .01) and peak breath alcohol concentration (β, −0.46; 95% CI, −0.87 to −0.06; <em>P</em> = .03) (<a href="#yoi240094f2" class="usa-link">Figure 2</a>). See the eMethods in <a href="#note-YOI240094-1-s" class="usa-link">Supplement 2</a> for additional model information and eTable 2 in <a href="#note-YOI240094-1-s" class="usa-link">Supplement 2</a> for full model results. Descriptive information on BrAC levels across time is depicted in <a href="#yoi240094f2" class="usa-link">Figure 2</a>; the exploratory analysis of mean BrAC yielded a significant medication effect (β = −0.48, 95% CI, −0.87 to −0.09; <em>P</em> = .02). Medication condition did not predict engagement (vs abstinence) in the self-administration task or duration of delay time (eResults in <a href="#note-YOI240094-1-s" class="usa-link">Supplement 2</a>).</p>
<figure class="fig xbox font-sm" id="yoi240094f2"><h4 class="obj_head">Figure 2.  Laboratory Self-Administration.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7b/11822619/567ad3206683/jamapsychiatry-e244789-g002.jpg" loading="lazy" height="3133" width="3892" alt="Figure 2. "></p>
<div class="p text-right font-secondary"><a href="figure/yoi240094f2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Laboratory self-administration, measured in estimated grams of alcohol (A) and peak measured breath alcohol concentration (BrAC; B). Bars depict posttreatment alcohol self-administration following treatment week 8 (0.5 mg/wk), controlling for pretreatment self-administration among those without missing data on the self-administration procedure (n = 25; 12 in the placebo group and 13 in the semaglutide group). C, Mean BrAC measured across 30-minute intervals as a function of treatment condition. D, Descriptive BrAC measurements during self-administration as a function of treatment condition and time point. Bars depict group means and whiskers standard errors.</p></figcaption></figure></section><section id="H2-9-YOI240094"><h3 class="pmc_sec_title">Weekly Outcomes</h3>
<p><a href="#yoi240094f3" class="usa-link">Figure 3</a> shows prospective changes in weekly outcomes. Medication effects were nonsignificant for drinks per calendar day (β, −0.27; 95% CI, −0.63 to 0.09; <em>P</em> = .17) and significant for drinks per drinking day (β, −0.41; 95% CI, −0.73 to −0.09; <em>P</em> = .04). A significant treatment-by-time interaction indicated greater reductions in heavy drinking days over time in the semaglutide group relative to the placebo group (β, 0.84; 95% CI, 0.71 to 0.99; <em>P</em> = .04). There was no evidence that semaglutide altered number of drinking vs abstinent days (β, 0.90; 95% CI, 0.73 to 1.12; <em>P</em> = .89). Semaglutide significantly reduced weekly craving (β, −0.39; 95% CI, −0.73 to −0.06; <em>P</em> = .01). The analysis among individuals reporting current cigarette smoking yielded a significant time-by-treatment interaction (β, −0.10; 95% CI, −0.16 to −0.03; <em>P</em> = .005), indicating relatively greater declines in cigarettes per day in the semaglutide vs placebo group over time (eFigure 2 in <a href="#note-YOI240094-1-s" class="usa-link">Supplement 2</a>; eTable 3 in <a href="#note-YOI240094-1-s" class="usa-link">Supplement 2</a> presents all model results for weekly outcomes).</p>
<figure class="fig xbox font-sm" id="yoi240094f3"><h4 class="obj_head">Figure 3.  Prospective Changes in Weekly Alcohol Outcomes.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7b/11822619/5f0c2167ed74/jamapsychiatry-e244789-g003.jpg" loading="lazy" height="4442" width="3892" alt="Figure 3. "></p>
<div class="p text-right font-secondary"><a href="figure/yoi240094f3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>A, n = 39-48 across weeks (18-24 in the placebo group and 21-24 in the semaglutide group). B, n = 31-48 (15-24 in the placebo group and 16-24 in the semaglutide group). C, n = 39-48 (18-24 in the placebo group and 21-24 in the semaglutide group). D, n = 39-48 (18-24 in the placebo group and 21-24 in the semaglutide group). E, n = 41-48 (19-24 in the placebo group and 22-24 in the semaglutide group). F, n = 41-48 (19-24 in the placebo group and 22-24 in the semaglutide group). Alcohol craving was measured via the Penn Alcohol Craving Scale (0-30). Data points depict group means and standard errors for weekly measurements of the outcome. Medication commenced at week 1. Weekly time points indicate data collected at the end of the week following that week’s injection (eg, week 1 drinking data were measured at week 2 and reflect the week following the week 1 injection).</p></figcaption></figure><p><a href="#yoi240094f4" class="usa-link">Figure 4</a>A-E depicts monthly changes from baseline with estimated effect sizes. Medication effect sizes were mostly small (by convention, Cohen <em>d</em> = 0.20) through week 4 and increased during weeks 5 to 8, with large effect sizes (defined as <em>d</em> = 0.80) observed for drinks per drinking day and heavy drinking days. Comparing the proportion of participants with zero heavy drinking days by group and treatment period (<a href="#yoi240094f4" class="usa-link">Figure 4</a>F) showed that the likelihood of zero heavy drinking days increased significantly from weeks 1 through 4 to 5 through 8 in the semaglutide group (<em>z</em> score, −2.93; <em>P</em> = .003), with no other significant comparisons.</p>
<figure class="fig xbox font-sm" id="yoi240094f4"><h4 class="obj_head">Figure 4.  Medication Group Differences in Weekly Drinking and Craving as a Function of Treatment Period.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e7b/11822619/1dd8947048c3/jamapsychiatry-e244789-g004.jpg" loading="lazy" height="3075" width="3892" alt="Figure 4. "></p>
<div class="p text-right font-secondary"><a href="figure/yoi240094f4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>A-E, Bars depict group means for changes from baseline on alcohol consumption and craving outcomes during treatment weeks 1-4 (0.25 mg/wk) and 5-8 (0.5 mg/wk) and whiskers indicate standard errors. Effect size estimates (Cohen <em>d</em>) reflect medication vs placebo group differences on the outcomes presented. Conventional benchmarks are <em>d</em> = 0.20 for a small effect, <em>d</em> = 0.5 for a medium effect, and <em>d</em> = 0.8 for a large effect, Numbers of participants across weeks were 43-47 for all models (placebo: 23 in weeks 1-4 and 20 in weeks 5-8; semaglutide: 24 in weeks 1-4 and 23 in weeks 5-8). For visual presentation, panel C excludes the data from 1 participant with an extreme outlier &gt;4 SD above the mean. F, Proportion of participants with zero heavy drinking days by treatment condition and dose (weeks 1-4, 0.25 mg/wk; weeks 5-8, 0.5 mg/wk).</p>
<p><sup>a</sup><em>P</em> &lt; .005.</p></figcaption></figure></section><section id="H2-10-YOI240094"><h3 class="pmc_sec_title">Weight and Safety and Adverse Effect Outcomes</h3>
<p>Body weight (kg) change at discharge averaged −5% in the semaglutide group (mean [SD], −5.05% [3.56] vs 0.18% [2.5] in the placebo group; time-by-treatment interaction: β, −0.07; 95% CI, −0.08 to −0.05; <em>P</em> &lt; .001) (<a href="#yoi240094f3" class="usa-link">Figure 3</a>). No significant medication effects for hemoglobin A<sub>1c</sub>, blood pressure, or depression scores were observed. Participants treated with semaglutide reported expected adverse effects, which were largely mild in severity (eTable 1 in <a href="#note-YOI240094-1-s" class="usa-link">Supplement 2</a>). No serious adverse events, adverse interactions with alcohol, or treatment-related discontinuations were recorded.</p></section></section><section id="H1-4-YOI240094"><h2 class="pmc_sec_title">Discussion</h2>
<p>Preclinical studies have demonstrated GLP-1RA–induced suppression of voluntary alcohol intake and attenuation of behavioral and neurochemical measures of alcohol reward.<sup><a href="#yoi240094r23" class="usa-link" aria-describedby="yoi240094r23">23</a>,<a href="#yoi240094r24" class="usa-link" aria-describedby="yoi240094r24">24</a>,<a href="#yoi240094r25" class="usa-link" aria-describedby="yoi240094r25">25</a>,<a href="#yoi240094r26" class="usa-link" aria-describedby="yoi240094r26">26</a></sup> Although most of these studies tested older GLP-1RAs (including exenatide and liraglutide), recent studies show that semaglutide reduces self-administration in mice, rats, and nonhuman primates.<sup><a href="#yoi240094r30" class="usa-link" aria-describedby="yoi240094r30">30</a>,<a href="#yoi240094r31" class="usa-link" aria-describedby="yoi240094r31">31</a>,<a href="#yoi240094r32" class="usa-link" aria-describedby="yoi240094r32">32</a>,<a href="#yoi240094r33" class="usa-link" aria-describedby="yoi240094r33">33</a></sup> Separately, anecdotal and media reports of incidental reductions in alcohol use, first noted with older GLP-1RAs,<sup><a href="#yoi240094r44" class="usa-link" aria-describedby="yoi240094r44">44</a></sup> have increased markedly alongside escalations in semaglutide prescriptions.<sup><a href="#yoi240094r21" class="usa-link" aria-describedby="yoi240094r21">21</a>,<a href="#yoi240094r22" class="usa-link" aria-describedby="yoi240094r22">22</a></sup> Off-label prescribing of GLP-1RAs for AUD is already reported, necessitating data from controlled trials.<sup><a href="#yoi240094r21" class="usa-link" aria-describedby="yoi240094r21">21</a>,<a href="#yoi240094r34" class="usa-link" aria-describedby="yoi240094r34">34</a></sup></p>
<p>This prospective clinical trial examined changes in laboratory and naturalistic alcohol consumption following weekly semaglutide treatment. Residualized change models of laboratory self-administration indicated that semaglutide reduced g-ETOH and peak BrAC among participants who engaged in a self-administration task at posttreatment, with evidence of medium to large effect sizes. Additionally, an exploratory analysis found that semaglutide reduced mean BrAC across the posttreatment self-administration session, with descriptive data suggesting the possibility of earlier de-escalation in consumption among participants treated with semaglutide, perhaps consistent with a satiety effect (<a href="#yoi240094f2" class="usa-link">Figure 2</a>). For weekly drinking outcomes, medication effects on number of drinks per calendar day were nonsignificant; however, semaglutide significantly reduced alcohol craving and drinks per drinking day, also interacting with treatment week to predict reductions in heavy drinking days. Consequently, the proportion of participants with zero heavy drinking days increased significantly in the semaglutide group across the 2 dose phases. Semaglutide did not alter the proportion of abstinent vs drinking days. Though limited by a small subsample, an analysis of participants reporting current cigarette use revealed a significant medication-by-time interaction on changes in cigarettes per day.</p>
<p>Recent reports linking semaglutide or related drugs (including tirzepatide, a GLP-1/GIP dual receptor agonist) to alcohol-related outcomes have relied on observational or anecdotal data.<sup><a href="#yoi240094r22" class="usa-link" aria-describedby="yoi240094r22">22</a>,<a href="#yoi240094r45" class="usa-link" aria-describedby="yoi240094r45">45</a>,<a href="#yoi240094r46" class="usa-link" aria-describedby="yoi240094r46">46</a></sup> The only prior randomized trial in an AUD sample<sup><a href="#yoi240094r47" class="usa-link" aria-describedby="yoi240094r47">47</a></sup> found that exenatide—the first approved GLP-1RA—did not reduce overall consumption, but exploratory analyses indicated potential efficacy within a high-BMI (≥30) subgroup.<sup><a href="#yoi240094r47" class="usa-link" aria-describedby="yoi240094r47">47</a></sup> Exploratory subgroup comparisons here (eFigure 3 in <a href="#note-YOI240094-1-s" class="usa-link">Supplement 2</a>) did not indicate a similar pattern, suggesting the need to study efficacy across BMI levels. Although differences in sample characteristics or study design could contribute to differential evidence for efficacy across these 2 trials, the superior efficacy of semaglutide vs exenatide is likely the simplest interpretation.</p>
<p>Preliminary estimates of medication effect sizes yielded notable findings. Effect sizes approximated the small range (Cohen <em>d</em> = 0.20) during weeks 1 to 4 (0.25 mg/week), increasing during weeks 4 to 8 (0.5 mg/week). Effect sizes for heavy drinking days and drinks per drinking day reached the large range (<em>d</em> &gt; 0.80) at the 0.5 mg/week dose, with objective laboratory data also suggesting large effect sizes on self-administration. By comparison, approved (and effective) AUD medications, including naltrexone, generally show small effect sizes in both clinical trials<sup><a href="#yoi240094r15" class="usa-link" aria-describedby="yoi240094r15">15</a>,<a href="#yoi240094r48" class="usa-link" aria-describedby="yoi240094r48">48</a>,<a href="#yoi240094r49" class="usa-link" aria-describedby="yoi240094r49">49</a></sup> and laboratory studies of self-administration and other outcomes.<sup><a href="#yoi240094r35" class="usa-link" aria-describedby="yoi240094r35">35</a>,<a href="#yoi240094r50" class="usa-link" aria-describedby="yoi240094r50">50</a></sup> While preliminary, the current effect size estimates are promising, especially considering those observed for FDA-approved AUD treatments.<sup><a href="#yoi240094r51" class="usa-link" aria-describedby="yoi240094r51">51</a>,<a href="#yoi240094r52" class="usa-link" aria-describedby="yoi240094r52">52</a></sup> These findings are especially notable in that this study used the 2 lowest clinical doses of semaglutide, whereas doses for weight reduction reach 2.4 mg/week. Considering greater effects of semaglutide on other medical outcomes (eg, weight loss) with increasing dose and treatment duration, higher doses would presumably yield greater effects on alcohol reduction. However, safety profiles at higher doses in this population require careful evaluation. The extent of weight loss in the semaglutide group (−5% on average), though similar to that observed at these doses in populations with overweight or obesity, has additional safety risks for people with normal or low weight, necessitating evaluation of which doses (and which GLP-1RAs) optimally balance safety and efficacy in substance use disorder samples.</p>
<p>The focus on non–treatment-seeking participants has important considerations, one being that semaglutide-related reductions in drinking quantity occurred absent volitional attempts to reduce drinking. In contrast to treatment-seeking participants, this sample is arguably representative of the majority of those with AUD exposed to GLP-1RAs in general medical settings. Considering both the rapid adoption of GLP-1RAs and the demonstrated health benefits of net reductions in alcohol use,<sup><a href="#yoi240094r53" class="usa-link" aria-describedby="yoi240094r53">53</a></sup> GLP-1RA–related reductions in consumption—when considered at large scale—could lead to improved health outcomes that are not currently appreciated. Recent pharmacoepidemiology results<sup><a href="#yoi240094r54" class="usa-link" aria-describedby="yoi240094r54">54</a></sup> appear consistent with this possibility. Moreover, given low utilization of FDA-approved AUD therapies,<sup><a href="#yoi240094r11" class="usa-link" aria-describedby="yoi240094r11">11</a></sup> the number of those with AUD receiving GLP-1RA medications already greatly exceeds the number who receive FDA-approved AUD medications. In this context, the broad uptake of GLP-1RAs presents an ideal scenario for medication repurposing, with potential to help reduce the wide treatment gap associated with AUD.</p>
<p>Evidence that semaglutide showed minimal effects on proportion of drinking vs abstinence days—with the largest effect sizes observed for drinking quantity and heavy drinking—also has possible clinical implications. The potential for selective effects on quantitative reductions in drinking could render GLP-1RAs well suited to nonabstinence goals,<sup><a href="#yoi240094r14" class="usa-link" aria-describedby="yoi240094r14">14</a>,<a href="#yoi240094r15" class="usa-link" aria-describedby="yoi240094r15">15</a>,<a href="#yoi240094r16" class="usa-link" aria-describedby="yoi240094r16">16</a>,<a href="#yoi240094r53" class="usa-link" aria-describedby="yoi240094r53">53</a></sup> which are a preferred treatment goal for many with AUD. Notably, laboratory self-administration results also suggested no medication effects on delay time or abstinence (eResults in <a href="#note-YOI240094-1-s" class="usa-link">Supplement 2</a>). Studies with treatment-seeking samples are needed to determine whether GLP-1RAs can facilitate abstinence or prevent relapse.</p>
<p>Though limited by a small subsample, a notable secondary finding was evidence for medication-related reductions in cigarettes per day among those reporting cigarette use. Based on preclinical evidence that GLP-1RAs reduce voluntary nicotine self-administration,<sup><a href="#yoi240094r55" class="usa-link" aria-describedby="yoi240094r55">55</a></sup> recent studies have evaluated GLP-1RAs for smoking cessation and prevention of postcessation weight gain.<sup><a href="#yoi240094r56" class="usa-link" aria-describedby="yoi240094r56">56</a>,<a href="#yoi240094r57" class="usa-link" aria-describedby="yoi240094r57">57</a></sup> Should GLP-1RAs prove efficacious for both alcohol reduction and smoking cessation, potential health implications could be substantial. Alcohol and cigarette use (along with obesity) are leading preventable causes of mortality and preventable cancer deaths,<sup><a href="#yoi240094r58" class="usa-link" aria-describedby="yoi240094r58">58</a>,<a href="#yoi240094r59" class="usa-link" aria-describedby="yoi240094r59">59</a></sup> making individuals who smoke and drink heavily—including those with overweight or obesity—a priority population.<sup><a href="#yoi240094r60" class="usa-link" aria-describedby="yoi240094r60">60</a>,<a href="#yoi240094r61" class="usa-link" aria-describedby="yoi240094r61">61</a>,<a href="#yoi240094r62" class="usa-link" aria-describedby="yoi240094r62">62</a></sup> Despite efforts to advance pharmacotherapies for concurrent AUD and tobacco use disorder,<sup><a href="#yoi240094r63" class="usa-link" aria-describedby="yoi240094r63">63</a>,<a href="#yoi240094r64" class="usa-link" aria-describedby="yoi240094r64">64</a>,<a href="#yoi240094r65" class="usa-link" aria-describedby="yoi240094r65">65</a>,<a href="#yoi240094r66" class="usa-link" aria-describedby="yoi240094r66">66</a></sup> no medication is approved for both conditions.<sup><a href="#yoi240094r62" class="usa-link" aria-describedby="yoi240094r62">62</a></sup></p>
<section id="H2-11-YOI240094"><h3 class="pmc_sec_title">Limitations</h3>
<p>Among several study limitations are the modest sample size and short-term treatment duration, both reflecting the phase 2 stage of this trial. The use of low-dose semaglutide to maximize safety and feasibility likely limited detection of significant effects. However, the effect sizes observed at low doses are encouraging and provide information for estimating sample sizes for future trials. Another limitation is the moderate level of AUD severity of this sample, with consumption levels below those of most treatment-seeking samples. While this sample might reasonably approximate populations encountered in general medical settings, studies with heavier drinkers are necessary. Larger trials that address these questions while prioritizing FDA-accepted efficacy end points<sup><a href="#yoi240094r40" class="usa-link" aria-describedby="yoi240094r40">40</a></sup> will ultimately inform the potential of GLP-1RAs as an emergent class of AUD therapies.<sup><a href="#yoi240094r21" class="usa-link" aria-describedby="yoi240094r21">21</a>,<a href="#yoi240094r34" class="usa-link" aria-describedby="yoi240094r34">34</a></sup></p></section></section><section id="H1-5-YOI240094"><h2 class="pmc_sec_title">Conclusions</h2>
<p>Since the FDA approval of the first AUD medication (disulfiram) in 1951, only 2 medications (naltrexone and acamprosate) have received subsequent FDA approval for AUD.<sup><a href="#yoi240094r12" class="usa-link" aria-describedby="yoi240094r12">12</a>,<a href="#yoi240094r52" class="usa-link" aria-describedby="yoi240094r52">52</a></sup> The rate of 1 new approval every 20 to 25 years is inadequate and is in stark contrast with the pace of FDA approvals for diabetes medications, which now outnumber AUD medication approvals 20-fold. Should additional phase 2 and phase 3 clinical trials support repurposing 1 or more GLP-1RAs for AUD, these treatments could have broad clinical infiltration, with potential to bypass many traditional impediments to the uptake of AUD medications, including low public and provider awareness and stigma toward AUD treatments. Importantly, the increasing clinical uptake of GLP-1RAs would presumably reduce prescribing barriers, including in primary care, where AUD treatments have proven difficult to bring to scale. These possibilities call for larger clinical trials to evaluate efficacy of GLP-1RAs and other incretin therapies for AUD. Given numerous GLP-1RAs at various stages of development, future studies need not be limited to a single medication.</p></section><section id="note-YOI240094-1"><section class="sm xbox font-sm" id="note-YOI240094-1-s"><div class="caption p">
<span>Supplement 1.</span><p>Trial protocol</p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/11822619/bin/jamapsychiatry-e244789-s001.pdf" data-ga-action="click_feat_suppl" class="usa-link">jamapsychiatry-e244789-s001.pdf</a><sup> (6.4MB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="supplementary-material2"><div class="caption p">
<span>Supplement 2.</span><p>eMethods. Supplementary protocol and analysis plan information</p>
<p>eResults. Supplementary results information</p>
<p>eTable 1. Adverse events by medication group and treatment dose/month</p>
<p>eTable 2. Full results for all models examining laboratory self-administration</p>
<p>eTable 3. Full results for linear mixed models examining changes in weekly outcomes</p>
<p>eFigure 1. Duration of delay in laboratory consumption by medication group</p>
<p>eFigure 2. Mean cigarettes per day by week in semaglutide and placebo groups (n = 13)</p>
<p>eFigure 3. Descriptive comparison of drinking outcomes by baseline body mass index (BMI)</p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/11822619/bin/jamapsychiatry-e244789-s002.pdf" data-ga-action="click_feat_suppl" class="usa-link">jamapsychiatry-e244789-s002.pdf</a><sup> (1.3MB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="supplementary-material3"><div class="caption p">
<span>Supplement 3.</span><p>Data sharing statement</p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/11822619/bin/jamapsychiatry-e244789-s003.pdf" data-ga-action="click_feat_suppl" class="usa-link">jamapsychiatry-e244789-s003.pdf</a><sup> (12.5KB, pdf) </sup>
</div></div></section></section><section id="REF-YOI240094" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="REF-YOI240094_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="yoi240094r1">
<span class="label">1.</span><cite>Shield K, Manthey J, Rylett M, et al. National, regional, and global burdens of disease from 2000 to 2016 attributable to alcohol use: a comparative risk assessment study. Lancet Public Health. 2020;5(1):e51-e61. doi: 10.1016/S2468-2667(19)30231-2
</cite> [<a href="https://doi.org/10.1016/S2468-2667(19)30231-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31910980/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Public%20Health&amp;title=National,%20regional,%20and%20global%20burdens%20of%20disease%20from%202000%20to%202016%20attributable%20to%20alcohol%20use:%20a%20comparative%20risk%20assessment%20study&amp;volume=5&amp;issue=1&amp;publication_year=2020&amp;pages=e51-e61&amp;pmid=31910980&amp;doi=10.1016/S2468-2667(19)30231-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r2">
<span class="label">2.</span><cite>Global Status Report on Alcohol and Health and Treatment of Substance Use Disorders. World Health Organization; 2024.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Global%20Status%20Report%20on%20Alcohol%20and%20Health%20and%20Treatment%20of%20Substance%20Use%20Disorders&amp;publication_year=2024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r3">
<span class="label">3.</span><cite>Esser MB, Sherk A, Liu Y, Naimi TS. Deaths from excessive alcohol use—United States, 2016-2021. MMWR Morb Mortal Wkly Rep. 2024;73(8):154-161. doi: 10.15585/mmwr.mm7308a1
</cite> [<a href="https://doi.org/10.15585/mmwr.mm7308a1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10907037/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38421934/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=MMWR%20Morb%20Mortal%20Wkly%20Rep&amp;title=Deaths%20from%20excessive%20alcohol%20use%E2%80%94United%20States,%202016-2021&amp;volume=73&amp;issue=8&amp;publication_year=2024&amp;pages=154-161&amp;pmid=38421934&amp;doi=10.15585/mmwr.mm7308a1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r4">
<span class="label">4.</span><cite>Manthey J, Shield KD, Rylett M, Hasan OSM, Probst C, Rehm J. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. Lancet. 2019;393(10190):2493-2502. doi: 10.1016/S0140-6736(18)32744-2
</cite> [<a href="https://doi.org/10.1016/S0140-6736(18)32744-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31076174/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Global%20alcohol%20exposure%20between%201990%20and%202017%20and%20forecasts%20until%202030:%20a%20modelling%20study&amp;volume=393&amp;issue=10190&amp;publication_year=2019&amp;pages=2493-2502&amp;pmid=31076174&amp;doi=10.1016/S0140-6736(18)32744-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r5">
<span class="label">5.</span><cite>Deutsch-Link S, Jiang Y, Peery AF, Barritt AS, Bataller R, Moon AM. Alcohol-associated liver disease mortality increased from 2017 to 2020 and accelerated during the COVID-19 pandemic. Clin Gastroenterol Hepatol. 2022;20(9):2142-2144.e2. doi: 10.1016/j.cgh.2022.03.017
</cite> [<a href="https://doi.org/10.1016/j.cgh.2022.03.017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8933289/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35314353/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Gastroenterol%20Hepatol&amp;title=Alcohol-associated%20liver%20disease%20mortality%20increased%20from%202017%20to%202020%20and%20accelerated%20during%20the%20COVID-19%20pandemic&amp;volume=20&amp;issue=9&amp;publication_year=2022&amp;pages=2142-2144.e2&amp;pmid=35314353&amp;doi=10.1016/j.cgh.2022.03.017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r6">
<span class="label">6.</span><cite>White AM, Castle IP, Powell PA, Hingson RW, Koob GF. Alcohol-related deaths during the COVID-19 pandemic. JAMA. 2022;327(17):1704-1706. doi: 10.1001/jama.2022.4308
</cite> [<a href="https://doi.org/10.1001/jama.2022.4308" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8933830/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35302593/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Alcohol-related%20deaths%20during%20the%20COVID-19%20pandemic&amp;volume=327&amp;issue=17&amp;publication_year=2022&amp;pages=1704-1706&amp;pmid=35302593&amp;doi=10.1001/jama.2022.4308&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r7">
<span class="label">7.</span><cite>Julien J, Ayer T, Bethea ED, Tapper EB, Chhatwal J. Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019-40: a modelling study. Lancet Public Health. 2020;5(6):e316-e323. doi: 10.1016/S2468-2667(20)30062-1
</cite> [<a href="https://doi.org/10.1016/S2468-2667(20)30062-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32504584/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Public%20Health&amp;title=Projected%20prevalence%20and%20mortality%20associated%20with%20alcohol-related%20liver%20disease%20in%20the%20USA,%202019-40:%20a%20modelling%20study&amp;volume=5&amp;issue=6&amp;publication_year=2020&amp;pages=e316-e323&amp;pmid=32504584&amp;doi=10.1016/S2468-2667(20)30062-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r8">
<span class="label">8.</span><cite>Julien J, Ayer T, Tapper EB, Barbosa C, Dowd WN, Chhatwal J. Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: a modeling study. Hepatology. 2022;75(6):1480-1490. doi: 10.1002/hep.32272
</cite> [<a href="https://doi.org/10.1002/hep.32272" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9015640/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34878683/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Effect%20of%20increased%20alcohol%20consumption%20during%20COVID-19%20pandemic%20on%20alcohol-associated%20liver%20disease:%20a%20modeling%20study&amp;volume=75&amp;issue=6&amp;publication_year=2022&amp;pages=1480-1490&amp;pmid=34878683&amp;doi=10.1002/hep.32272&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r9">
<span class="label">9.</span><cite>Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of <em>DSM-5</em> alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015;72(8):757-766. doi: 10.1001/jamapsychiatry.2015.0584
</cite> [<a href="https://doi.org/10.1001/jamapsychiatry.2015.0584" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5240584/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26039070/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Psychiatry&amp;title=Epidemiology%20of%20DSM-5%20alcohol%20use%20disorder:%20results%20from%20the%20National%20Epidemiologic%20Survey%20on%20Alcohol%20and%20Related%20Conditions%20III&amp;volume=72&amp;issue=8&amp;publication_year=2015&amp;pages=757-766&amp;pmid=26039070&amp;doi=10.1001/jamapsychiatry.2015.0584&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r10">
<span class="label">10.</span><cite>Substance Abuse and Mental Health Services Administration . National survey on drug use and health. Table 5.9A—alcohol use disorder in past year: among people aged 12 or older; by age group and demographic characteristics, numbers in thousands, 2021 and 2022. <a href="https://www.samhsa.gov/data/sites/default/files/reports/rpt42728/NSDUHDetailedTabs2022/NSDUHDetailedTabs2022/NSDUHDetTabsSect5pe2022.htm#tab5.9a" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.samhsa.gov/data/sites/default/files/reports/rpt42728/NSDUHDetailedTabs2022/NSDUHDetailedTabs2022/NSDUHDetTabsSect5pe2022.htm#tab5.9a</a></cite>
</li>
<li id="yoi240094r11">
<span class="label">11.</span><cite>Han B, Jones CM, Einstein EB, Powell PA, Compton WM. Use of medications for alcohol use disorder in the US: results from the 2019 National Survey on Drug Use and Health. JAMA Psychiatry. 2021;78(8):922-924. doi: 10.1001/jamapsychiatry.2021.1271
</cite> [<a href="https://doi.org/10.1001/jamapsychiatry.2021.1271" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8209593/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34132744/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Psychiatry&amp;title=Use%20of%20medications%20for%20alcohol%20use%20disorder%20in%20the%20US:%20results%20from%20the%202019%20National%20Survey%20on%20Drug%20Use%20and%20Health&amp;volume=78&amp;issue=8&amp;publication_year=2021&amp;pages=922-924&amp;pmid=34132744&amp;doi=10.1001/jamapsychiatry.2021.1271&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r12">
<span class="label">12.</span><cite>Koob GF. Alcohol use disorder treatment: problems and solutions. Annu Rev Pharmacol Toxicol. 2024;64:255-275. doi: 10.1146/annurev-pharmtox-031323-115847
</cite> [<a href="https://doi.org/10.1146/annurev-pharmtox-031323-115847" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38261428/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annu%20Rev%20Pharmacol%20Toxicol&amp;title=Alcohol%20use%20disorder%20treatment:%20problems%20and%20solutions&amp;volume=64&amp;publication_year=2024&amp;pages=255-275&amp;pmid=38261428&amp;doi=10.1146/annurev-pharmtox-031323-115847&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r13">
<span class="label">13.</span><cite>Witkiewitz K, Litten RZ, Leggio L. Advances in the science and treatment of alcohol use disorder. Sci Adv. 2019;5(9):eaax4043. doi: 10.1126/sciadv.aax4043
</cite> [<a href="https://doi.org/10.1126/sciadv.aax4043" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6760932/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31579824/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Adv&amp;title=Advances%20in%20the%20science%20and%20treatment%20of%20alcohol%20use%20disorder&amp;volume=5&amp;issue=9&amp;publication_year=2019&amp;pages=eaax4043&amp;pmid=31579824&amp;doi=10.1126/sciadv.aax4043&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r14">
<span class="label">14.</span><cite>Hasin DS, Wall M, Witkiewitz K, et al. ; Alcohol Clinical Trials Initiative (ACTIVE) Workgroup . Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population. Lancet Psychiatry. 2017;4(6):469-476. doi: 10.1016/S2215-0366(17)30130-X
</cite> [<a href="https://doi.org/10.1016/S2215-0366(17)30130-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5536861/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28456501/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Psychiatry&amp;title=Change%20in%20non-abstinent%20WHO%20drinking%20risk%20levels%20and%20alcohol%20dependence:%20a%203%20year%20follow-up%20study%20in%20the%20US%20general%20population&amp;volume=4&amp;issue=6&amp;publication_year=2017&amp;pages=469-476&amp;pmid=28456501&amp;doi=10.1016/S2215-0366(17)30130-X&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r15">
<span class="label">15.</span><cite>Witkiewitz K, Hallgren KA, Kranzler HR, et al. Clinical validation of reduced alcohol consumption after treatment for alcohol dependence using the World Health Organization risk drinking levels. Alcohol Clin Exp Res. 2017;41(1):179-186. doi: 10.1111/acer.13272
</cite> [<a href="https://doi.org/10.1111/acer.13272" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5205540/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28019652/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Alcohol%20Clin%20Exp%20Res&amp;title=Clinical%20validation%20of%20reduced%20alcohol%20consumption%20after%20treatment%20for%20alcohol%20dependence%20using%20the%20World%20Health%20Organization%20risk%20drinking%20levels&amp;volume=41&amp;issue=1&amp;publication_year=2017&amp;pages=179-186&amp;pmid=28019652&amp;doi=10.1111/acer.13272&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r16">
<span class="label">16.</span><cite>Aldridge AP, Zarkin GA, Dowd WN, et al. The relationship between reductions in WHO risk drinking levels during treatment and subsequent healthcare costs for the ACTIVE Workgroup. J Addict Med. 2022;16(4):425-432. doi: 10.1097/ADM.0000000000000925
</cite> [<a href="https://doi.org/10.1097/ADM.0000000000000925" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9163210/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34864785/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Addict%20Med&amp;title=The%20relationship%20between%20reductions%20in%20WHO%20risk%20drinking%20levels%20during%20treatment%20and%20subsequent%20healthcare%20costs%20for%20the%20ACTIVE%20Workgroup&amp;volume=16&amp;issue=4&amp;publication_year=2022&amp;pages=425-432&amp;pmid=34864785&amp;doi=10.1097/ADM.0000000000000925&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r17">
<span class="label">17.</span><cite>Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47(11):1873-1888. doi: 10.2337/dci24-0003
</cite> [<a href="https://doi.org/10.2337/dci24-0003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38843460/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&amp;title=Efficacy%20and%20safety%20of%20GLP-1%20medicines%20for%20type%202%20diabetes%20and%20obesity&amp;volume=47&amp;issue=11&amp;publication_year=2024&amp;pages=1873-1888&amp;pmid=38843460&amp;doi=10.2337/dci24-0003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r18">
<span class="label">18.</span><cite>Drucker DJ. The GLP-1 journey: from discovery science to therapeutic impact. J Clin Invest. 2024;134(2):e175634. doi: 10.1172/JCI175634
</cite> [<a href="https://doi.org/10.1172/JCI175634" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10786682/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38226625/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Invest&amp;title=The%20GLP-1%20journey:%20from%20discovery%20science%20to%20therapeutic%20impact&amp;volume=134&amp;issue=2&amp;publication_year=2024&amp;pages=e175634&amp;pmid=38226625&amp;doi=10.1172/JCI175634&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r19">
<span class="label">19.</span><cite>Drucker DJ. The benefits of GLP-1 drugs beyond obesity. Science. 2024;385(6706):258-260. doi: 10.1126/science.adn4128
</cite> [<a href="https://doi.org/10.1126/science.adn4128" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39024455/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=The%20benefits%20of%20GLP-1%20drugs%20beyond%20obesity&amp;volume=385&amp;issue=6706&amp;publication_year=2024&amp;pages=258-260&amp;pmid=39024455&amp;doi=10.1126/science.adn4128&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r20">
<span class="label">20.</span><cite>Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008
</cite> [<a href="https://doi.org/10.1016/j.tcm.2021.12.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9209591/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34942372/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Trends%20Cardiovasc%20Med&amp;title=Semaglutide%20for%20the%20treatment%20of%20obesity&amp;volume=33&amp;issue=3&amp;publication_year=2023&amp;pages=159-166&amp;pmid=34942372&amp;doi=10.1016/j.tcm.2021.12.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r21">
<span class="label">21.</span><cite>Leggio L, Hendershot CS, Farokhnia M, et al. GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Nat Med. 2023;29(12):2993-2995. doi: 10.1038/s41591-023-02634-8
</cite> [<a href="https://doi.org/10.1038/s41591-023-02634-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12320759/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38001271/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Med&amp;title=GLP-1%20receptor%20agonists%20are%20promising%20but%20unproven%20treatments%20for%20alcohol%20and%20substance%20use%20disorders&amp;volume=29&amp;issue=12&amp;publication_year=2023&amp;pages=2993-2995&amp;pmid=38001271&amp;doi=10.1038/s41591-023-02634-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r22">
<span class="label">22.</span><cite>Bremmer MP, Hendershot CS. Social media as pharmacovigilance: the potential for patient reports to inform clinical research on glucagon-like peptide 1 (glp-1) receptor agonists for substance use disorders. J Stud Alcohol Drugs. 2024;85(1):5-11. doi: 10.15288/jsad.23-00318
</cite> [<a href="https://doi.org/10.15288/jsad.23-00318" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10846600/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37917019/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Stud%20Alcohol%20Drugs&amp;title=Social%20media%20as%20pharmacovigilance:%20the%20potential%20for%20patient%20reports%20to%20inform%20clinical%20research%20on%20glucagon-like%20peptide%201%20(glp-1)%20receptor%20agonists%20for%20substance%20use%20disorders&amp;volume=85&amp;issue=1&amp;publication_year=2024&amp;pages=5-11&amp;pmid=37917019&amp;doi=10.15288/jsad.23-00318&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r23">
<span class="label">23.</span><cite>Brunchmann A, Thomsen M, Fink-Jensen A. The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: a systematic review. Physiol Behav. 2019;206:232-242. doi: 10.1016/j.physbeh.2019.03.029
</cite> [<a href="https://doi.org/10.1016/j.physbeh.2019.03.029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6520118/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30946836/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Physiol%20Behav&amp;title=The%20effect%20of%20glucagon-like%20peptide-1%20(GLP-1)%20receptor%20agonists%20on%20substance%20use%20disorder%20(SUD)-related%20behavioural%20effects%20of%20drugs%20and%20alcohol:%20a%20systematic%20review&amp;volume=206&amp;publication_year=2019&amp;pages=232-242&amp;pmid=30946836&amp;doi=10.1016/j.physbeh.2019.03.029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r24">
<span class="label">24.</span><cite>Jerlhag E. Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1. Brain Res. 2020;1727:146562. doi: 10.1016/j.brainres.2019.146562
</cite> [<a href="https://doi.org/10.1016/j.brainres.2019.146562" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31759971/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Brain%20Res&amp;title=Alcohol-mediated%20behaviours%20and%20the%20gut-brain%20axis;%20with%20focus%20on%20glucagon-like%20peptide-1&amp;volume=1727&amp;publication_year=2020&amp;pages=146562&amp;pmid=31759971&amp;doi=10.1016/j.brainres.2019.146562&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r25">
<span class="label">25.</span><cite>Jerlhag E. The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. Front Pharmacol. 2023;14:1063033. doi: 10.3389/fphar.2023.1063033
</cite> [<a href="https://doi.org/10.3389/fphar.2023.1063033" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10097922/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37063267/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Pharmacol&amp;title=The%20therapeutic%20potential%20of%20glucagon-like%20peptide-1%20for%20persons%20with%20addictions%20based%20on%20findings%20from%20preclinical%20and%20clinical%20studies&amp;volume=14&amp;publication_year=2023&amp;pages=1063033&amp;pmid=37063267&amp;doi=10.3389/fphar.2023.1063033&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r26">
<span class="label">26.</span><cite>Klausen MK, Thomsen M, Wortwein G, Fink-Jensen A. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol. 2022;179(4):625-641. doi: 10.1111/bph.15677
</cite> [<a href="https://doi.org/10.1111/bph.15677" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8820218/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34532853/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Pharmacol&amp;title=The%20role%20of%20glucagon-like%20peptide%201%20(GLP-1)%20in%20addictive%20disorders&amp;volume=179&amp;issue=4&amp;publication_year=2022&amp;pages=625-641&amp;pmid=34532853&amp;doi=10.1111/bph.15677&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r27">
<span class="label">27.</span><cite>Fink-Jensen A, Vilsbøll T. Glucagon-like peptide-1 (GLP-1) analogues: a potential new treatment for alcohol use disorder?
Nord J Psychiatry. 2016;70(8):561-562. doi: 10.1080/08039488.2016.1176252
</cite> [<a href="https://doi.org/10.1080/08039488.2016.1176252" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27151395/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nord%20J%20Psychiatry&amp;title=Glucagon-like%20peptide-1%20(GLP-1)%20analogues:%20a%20potential%20new%20treatment%20for%20alcohol%20use%20disorder?&amp;volume=70&amp;issue=8&amp;publication_year=2016&amp;pages=561-562&amp;pmid=27151395&amp;doi=10.1080/08039488.2016.1176252&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r28">
<span class="label">28.</span><cite>Egecioglu E, Steensland P, Fredriksson I, Feltmann K, Engel JA, Jerlhag E. The glucagon-like peptide 1 analogue exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology. 2013;38(8):1259-1270. doi: 10.1016/j.psyneuen.2012.11.009
</cite> [<a href="https://doi.org/10.1016/j.psyneuen.2012.11.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23219472/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Psychoneuroendocrinology&amp;title=The%20glucagon-like%20peptide%201%20analogue%20exendin-4%20attenuates%20alcohol%20mediated%20behaviors%20in%20rodents&amp;volume=38&amp;issue=8&amp;publication_year=2013&amp;pages=1259-1270&amp;pmid=23219472&amp;doi=10.1016/j.psyneuen.2012.11.009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r29">
<span class="label">29.</span><cite>Vallöf D, Kalafateli AL, Jerlhag E. Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents. Psychoneuroendocrinology. 2019;103:284-295. doi: 10.1016/j.psyneuen.2019.02.006
</cite> [<a href="https://doi.org/10.1016/j.psyneuen.2019.02.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30771711/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Psychoneuroendocrinology&amp;title=Brain%20region%20specific%20glucagon-like%20peptide-1%20receptors%20regulate%20alcohol-induced%20behaviors%20in%20rodents&amp;volume=103&amp;publication_year=2019&amp;pages=284-295&amp;pmid=30771711&amp;doi=10.1016/j.psyneuen.2019.02.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r30">
<span class="label">30.</span><cite>Aranäs C, Edvardsson CE, Shevchouk OT, et al. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine. 2023;93:104642. doi: 10.1016/j.ebiom.2023.104642
</cite> [<a href="https://doi.org/10.1016/j.ebiom.2023.104642" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10363436/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37295046/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=EBioMedicine&amp;title=Semaglutide%20reduces%20alcohol%20intake%20and%20relapse-like%20drinking%20in%20male%20and%20female%20rats&amp;volume=93&amp;publication_year=2023&amp;pages=104642&amp;pmid=37295046&amp;doi=10.1016/j.ebiom.2023.104642&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r31">
<span class="label">31.</span><cite>Chuong V, Farokhnia M, Khom S, et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023;8(12):e170671. doi: 10.1172/jci.insight.170671
</cite> [<a href="https://doi.org/10.1172/jci.insight.170671" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10371247/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37192005/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JCI%20Insight&amp;title=The%20glucagon-like%20peptide-1%20(GLP-1)%20analogue%20semaglutide%20reduces%20alcohol%20drinking%20and%20modulates%20central%20GABA%20neurotransmission&amp;volume=8&amp;issue=12&amp;publication_year=2023&amp;pages=e170671&amp;pmid=37192005&amp;doi=10.1172/jci.insight.170671&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r32">
<span class="label">32.</span><cite>Fink-Jensen A, Wörtwein G, Klausen MK, et al. Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys. Psychopharmacology (Berl). Published online June 17, 2024. doi: 10.1007/s00213-024-06637-2
</cite> [<a href="https://doi.org/10.1007/s00213-024-06637-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11742737/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38884652/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Psychopharmacology%20(Berl)&amp;title=Effect%20of%20the%20glucagon-like%20peptide-1%20(GLP-1)%20receptor%20agonist%20semaglutide%20on%20alcohol%20consumption%20in%20alcohol-preferring%20male%20vervet%20monkeys&amp;publication_year=2024&amp;pmid=38884652&amp;doi=10.1007/s00213-024-06637-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r33">
<span class="label">33.</span><cite>Marty VN, Farokhnia M, Munier JJ, Mulpuri Y, Leggio L, Spigelman I. Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male Wistar rats. Front Neurosci. 2020;14:599646. doi: 10.3389/fnins.2020.599646
</cite> [<a href="https://doi.org/10.3389/fnins.2020.599646" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7785877/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33424537/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Neurosci&amp;title=Long-acting%20glucagon-like%20peptide-1%20receptor%20agonists%20suppress%20voluntary%20alcohol%20intake%20in%20male%20Wistar%20rats&amp;volume=14&amp;publication_year=2020&amp;pages=599646&amp;pmid=33424537&amp;doi=10.3389/fnins.2020.599646&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r34">
<span class="label">34.</span><cite>Volkow ND, Xu R. GLP-1R agonist medications for addiction treatment. Addiction. July 24, 2024. doi: 10.1111/add.16626
</cite> [<a href="https://doi.org/10.1111/add.16626" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39049203/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Addiction&amp;title=GLP-1R%20agonist%20medications%20for%20addiction%20treatment&amp;publication_year=2024&amp;pmid=39049203&amp;doi=10.1111/add.16626&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r35">
<span class="label">35.</span><cite>Hendershot CS, Wardell JD, Samokhvalov AV, Rehm J. Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies. Addict Biol. 2017;22(6):1515-1527. doi: 10.1111/adb.12425
</cite> [<a href="https://doi.org/10.1111/adb.12425" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6139429/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27411969/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Addict%20Biol&amp;title=Effects%20of%20naltrexone%20on%20alcohol%20self-administration%20and%20craving:%20meta-analysis%20of%20human%20laboratory%20studies&amp;volume=22&amp;issue=6&amp;publication_year=2017&amp;pages=1515-1527&amp;pmid=27411969&amp;doi=10.1111/adb.12425&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r36">
<span class="label">36.</span><cite>McKee SA, Harrison EL, O’Malley SS, et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry. 2009;66(2):185-190. doi: 10.1016/j.biopsych.2009.01.029
</cite> [<a href="https://doi.org/10.1016/j.biopsych.2009.01.029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2863311/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19249750/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biol%20Psychiatry&amp;title=Varenicline%20reduces%20alcohol%20self-administration%20in%20heavy-drinking%20smokers&amp;volume=66&amp;issue=2&amp;publication_year=2009&amp;pages=185-190&amp;pmid=19249750&amp;doi=10.1016/j.biopsych.2009.01.029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r37">
<span class="label">37.</span><cite>McKee SA, Verplaetse TL. A novel human laboratory alcohol self-administration paradigm for medication screening: modeling the ability to resist drinking and heavy drinking. Drug Alcohol Depend Rep. Published online September 4, 2022. doi: 10.1016/j.dadr.2022.100085
</cite> [<a href="https://doi.org/10.1016/j.dadr.2022.100085" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9481061/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36120181/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drug%20Alcohol%20Depend%20Rep&amp;title=A%20novel%20human%20laboratory%20alcohol%20self-administration%20paradigm%20for%20medication%20screening:%20modeling%20the%20ability%20to%20resist%20drinking%20and%20heavy%20drinking&amp;publication_year=2022&amp;pmid=36120181&amp;doi=10.1016/j.dadr.2022.100085&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r38">
<span class="label">38.</span><cite>Sobell LC, Sobell MB. Timeline Follow-Back: A Technique for Assessing Self-Reported Alcohol Consumption. Measuring Alcohol Consumption: Psychosocial and Biochemical Methods. Springer; 1992:41-72.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Timeline%20Follow-Back:%20A%20Technique%20for%20Assessing%20Self-Reported%20Alcohol%20Consumption.%20Measuring%20Alcohol%20Consumption:%20Psychosocial%20and%20Biochemical%20Methods&amp;publication_year=1992&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r39">
<span class="label">39.</span><cite>Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res. 1999;23(8):1289-1295. doi: 10.1111/j.1530-0277.1999.tb04349.x
</cite> [<a href="https://doi.org/10.1111/j.1530-0277.1999.tb04349.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10470970/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Alcohol%20Clin%20Exp%20Res&amp;title=Psychometric%20properties%20of%20the%20Penn%20Alcohol%20Craving%20Scale&amp;volume=23&amp;issue=8&amp;publication_year=1999&amp;pages=1289-1295&amp;pmid=10470970&amp;doi=10.1111/j.1530-0277.1999.tb04349.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r40">
<span class="label">40.</span><cite>Belnap MA, McManus KR, Grodin EN, Ray LA. Endpoints for pharmacotherapy trials for alcohol use disorder. Pharmaceut Med. 2024;38(4):291-302. doi: 10.1007/s40290-024-00526-x
</cite> [<a href="https://doi.org/10.1007/s40290-024-00526-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11272707/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38967906/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmaceut%20Med&amp;title=Endpoints%20for%20pharmacotherapy%20trials%20for%20alcohol%20use%20disorder&amp;volume=38&amp;issue=4&amp;publication_year=2024&amp;pages=291-302&amp;pmid=38967906&amp;doi=10.1007/s40290-024-00526-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r41">
<span class="label">41.</span><cite>Johnson BA, Ait-Daoud N, Roache JD. The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field. J Stud Alcohol Suppl. 2005;(15):157-167. doi: 10.15288/jsas.2005.s15.157
</cite> [<a href="https://doi.org/10.15288/jsas.2005.s15.157" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16223067/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Stud%20Alcohol%20Suppl&amp;title=The%20COMBINE%20SAFTEE:%20a%20structured%20instrument%20for%20collecting%20adverse%20events%20adapted%20for%20clinical%20studies%20in%20the%20alcoholism%20field&amp;issue=15&amp;publication_year=2005&amp;pages=157-167&amp;pmid=16223067&amp;doi=10.15288/jsas.2005.s15.157&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r42">
<span class="label">42.</span><cite>Lewinsohn PM, Seeley JR, Roberts RE, Allen NB. Center for Epidemiologic Studies Depression Scale (CES-D) as a screening instrument for depression among community-residing older adults. Psychol Aging. 1997;12(2):277-287. doi: 10.1037/0882-7974.12.2.277
</cite> [<a href="https://doi.org/10.1037/0882-7974.12.2.277" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9189988/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Psychol%20Aging&amp;title=Center%20for%20Epidemiologic%20Studies%20Depression%20Scale%20(CES-D)%20as%20a%20screening%20instrument%20for%20depression%20among%20community-residing%20older%20adults&amp;volume=12&amp;issue=2&amp;publication_year=1997&amp;pages=277-287&amp;pmid=9189988&amp;doi=10.1037/0882-7974.12.2.277&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r43">
<span class="label">43.</span><cite>Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest package: tests in linear mixed effects models. J Stat Softw. 2017;82(13). doi: 10.18637/jss.v082.i13</cite> [<a href="https://doi.org/10.18637/jss.v082.i13" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Stat%20Softw&amp;title=lmerTest%20package:%20tests%20in%20linear%20mixed%20effects%20models&amp;volume=82&amp;issue=13&amp;publication_year=2017&amp;doi=10.18637/jss.v082.i13&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r44">
<span class="label">44.</span><cite>Kalra S, Kalra B, Sharma A. Change in alcohol consumption following liraglutide initiation: a real life experience. American Diabetes Association Annual Meeting 2011 Poster 1029. Alexandria, Virginia; 2011.</cite> [<a href="https://scholar.google.com/scholar_lookup?Kalra%20S,%20Kalra%20B,%20Sharma%20A.%20Change%20in%20alcohol%20consumption%20following%20liraglutide%20initiation:%20a%20real%20life%20experience.%20American%20Diabetes%20Association%20Annual%20Meeting%202011%20Poster%201029.%20Alexandria,%20Virginia;%202011." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r45">
<span class="label">45.</span><cite>Quddos F, Hubshman Z, Tegge A, et al. Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep. 2023;13(1):20998. doi: 10.1038/s41598-023-48267-2
</cite> [<a href="https://doi.org/10.1038/s41598-023-48267-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10684505/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38017205/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Rep&amp;title=Semaglutide%20and%20tirzepatide%20reduce%20alcohol%20consumption%20in%20individuals%20with%20obesity&amp;volume=13&amp;issue=1&amp;publication_year=2023&amp;pages=20998&amp;pmid=38017205&amp;doi=10.1038/s41598-023-48267-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r46">
<span class="label">46.</span><cite>Richards JR, Dorand MF, Royal K, Mnajjed L, Paszkowiak M, Simmons WK. Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: a case series. J Clin Psychiatry. 2023;85(1):23m15068. doi: 10.4088/JCP.23m15068
</cite> [<a href="https://doi.org/10.4088/JCP.23m15068" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38019594/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Psychiatry&amp;title=Significant%20decrease%20in%20alcohol%20use%20disorder%20symptoms%20secondary%20to%20semaglutide%20therapy%20for%20weight%20loss:%20a%20case%20series&amp;volume=85&amp;issue=1&amp;publication_year=2023&amp;pages=23m15068&amp;pmid=38019594&amp;doi=10.4088/JCP.23m15068&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r47">
<span class="label">47.</span><cite>Klausen MK, Jensen ME, Møller M, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022;7(19):e159863. doi: 10.1172/jci.insight.159863
</cite> [<a href="https://doi.org/10.1172/jci.insight.159863" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9675448/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36066977/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JCI%20Insight&amp;title=Exenatide%20once%20weekly%20for%20alcohol%20use%20disorder%20investigated%20in%20a%20randomized,%20placebo-controlled%20clinical%20trial&amp;volume=7&amp;issue=19&amp;publication_year=2022&amp;pages=e159863&amp;pmid=36066977&amp;doi=10.1172/jci.insight.159863&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r48">
<span class="label">48.</span><cite>Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
Addiction. 2013;108(2):275-293. doi: 10.1111/j.1360-0443.2012.04054.x
</cite> [<a href="https://doi.org/10.1111/j.1360-0443.2012.04054.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3970823/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23075288/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Addiction&amp;title=Meta-analysis%20of%20naltrexone%20and%20acamprosate%20for%20treating%20alcohol%20use%20disorders:%20when%20are%20these%20medications%20most%20helpful?&amp;volume=108&amp;issue=2&amp;publication_year=2013&amp;pages=275-293&amp;pmid=23075288&amp;doi=10.1111/j.1360-0443.2012.04054.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r49">
<span class="label">49.</span><cite>Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;(12):CD001867. doi: 10.1002/14651858.CD001867.pub3
</cite> [<a href="https://doi.org/10.1002/14651858.CD001867.pub3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21154349/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cochrane%20Database%20Syst%20Rev&amp;title=Opioid%20antagonists%20for%20alcohol%20dependence&amp;issue=12&amp;publication_year=2010&amp;pages=CD001867&amp;pmid=21154349&amp;doi=10.1002/14651858.CD001867.pub3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r50">
<span class="label">50.</span><cite>Ray LA, Green R, Roche DJO, Magill M, Bujarski S. Naltrexone effects on subjective responses to alcohol in the human laboratory: a systematic review and meta-analysis. Addict Biol. 2019;24(6):1138-1152. doi: 10.1111/adb.12747
</cite> [<a href="https://doi.org/10.1111/adb.12747" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6819195/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31148304/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Addict%20Biol&amp;title=Naltrexone%20effects%20on%20subjective%20responses%20to%20alcohol%20in%20the%20human%20laboratory:%20a%20systematic%20review%20and%20meta-analysis&amp;volume=24&amp;issue=6&amp;publication_year=2019&amp;pages=1138-1152&amp;pmid=31148304&amp;doi=10.1111/adb.12747&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r51">
<span class="label">51.</span><cite>Kranzler HR, Hartwell EE. Medications for treating alcohol use disorder: a narrative review. Alcohol Clin Exp Res (Hoboken). 2023;47(7):1224-1237. doi: 10.1111/acer.15118
</cite> [<a href="https://doi.org/10.1111/acer.15118" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37526592/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Alcohol%20Clin%20Exp%20Res%20(Hoboken)&amp;title=Medications%20for%20treating%20alcohol%20use%20disorder:%20a%20narrative%20review&amp;volume=47&amp;issue=7&amp;publication_year=2023&amp;pages=1224-1237&amp;pmid=37526592&amp;doi=10.1111/acer.15118&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r52">
<span class="label">52.</span><cite>Leggio L, Falk DE, Ryan ML, Fertig J, Litten RZ. Medication development for alcohol use disorder: a focus on clinical studies. Handb Exp Pharmacol. 2020;258:443-462. doi: 10.1007/164_2019_295
</cite> [<a href="https://doi.org/10.1007/164_2019_295" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31628604/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Handb%20Exp%20Pharmacol&amp;title=Medication%20development%20for%20alcohol%20use%20disorder:%20a%20focus%20on%20clinical%20studies&amp;volume=258&amp;publication_year=2020&amp;pages=443-462&amp;pmid=31628604&amp;doi=10.1007/164_2019_295&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r53">
<span class="label">53.</span><cite>Gapstur SM, Bouvard V, Nethan ST, et al. The IARC perspective on alcohol reduction or cessation and cancer risk. N Engl J Med. 2023;389(26):2486-2494. doi: 10.1056/NEJMsr2306723
</cite> [<a href="https://doi.org/10.1056/NEJMsr2306723" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38157507/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=The%20IARC%20perspective%20on%20alcohol%20reduction%20or%20cessation%20and%20cancer%20risk&amp;volume=389&amp;issue=26&amp;publication_year=2023&amp;pages=2486-2494&amp;pmid=38157507&amp;doi=10.1056/NEJMsr2306723&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r54">
<span class="label">54.</span><cite>Wang L, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun. 2024;15(1):4548. doi: 10.1038/s41467-024-48780-6
</cite> [<a href="https://doi.org/10.1038/s41467-024-48780-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11133479/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38806481/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=Associations%20of%20semaglutide%20with%20incidence%20and%20recurrence%20of%20alcohol%20use%20disorder%20in%20real-world%20population&amp;volume=15&amp;issue=1&amp;publication_year=2024&amp;pages=4548&amp;pmid=38806481&amp;doi=10.1038/s41467-024-48780-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r55">
<span class="label">55.</span><cite>Herman RJ, Schmidt HD. Targeting GLP-1 receptors to reduce nicotine use disorder: preclinical and clinical evidence. Physiol Behav. 2024;281:114565. doi: 10.1016/j.physbeh.2024.114565
</cite> [<a href="https://doi.org/10.1016/j.physbeh.2024.114565" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11128349/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38663460/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Physiol%20Behav&amp;title=Targeting%20GLP-1%20receptors%20to%20reduce%20nicotine%20use%20disorder:%20preclinical%20and%20clinical%20evidence&amp;volume=281&amp;publication_year=2024&amp;pages=114565&amp;pmid=38663460&amp;doi=10.1016/j.physbeh.2024.114565&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r56">
<span class="label">56.</span><cite>Herman RJ, Hayes MR, Audrain-McGovern J, Ashare RL, Schmidt HD. Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats. Psychopharmacology (Berl). 2023;240(6):1373-1386. doi: 10.1007/s00213-023-06376-w
</cite> [<a href="https://doi.org/10.1007/s00213-023-06376-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11088902/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37129617/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Psychopharmacology%20(Berl)&amp;title=Liraglutide%20attenuates%20nicotine%20self-administration%20as%20well%20as%20nicotine%20seeking%20and%20hyperphagia%20during%20withdrawal%20in%20male%20and%20female%20rats&amp;volume=240&amp;issue=6&amp;publication_year=2023&amp;pages=1373-1386&amp;pmid=37129617&amp;doi=10.1007/s00213-023-06376-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r57">
<span class="label">57.</span><cite>Yammine L, Green CE, Kosten TR, et al. Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: a pilot randomized controlled trial. Nicotine Tob Res. 2021;23(10):1682-1690. doi: 10.1093/ntr/ntab066
</cite> [<a href="https://doi.org/10.1093/ntr/ntab066" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8517504/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33831213/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nicotine%20Tob%20Res&amp;title=Exenatide%20adjunct%20to%20nicotine%20patch%20facilitates%20smoking%20cessation%20and%20may%20reduce%20post-cessation%20weight%20gain:%20a%20pilot%20randomized%20controlled%20trial&amp;volume=23&amp;issue=10&amp;publication_year=2021&amp;pages=1682-1690&amp;pmid=33831213&amp;doi=10.1093/ntr/ntab066&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r58">
<span class="label">58.</span><cite>Islami F, Marlow EC, Thomson B, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, 2019. CA Cancer J Clin. 2024;74(5):405-432. doi: 10.3322/caac.21858
</cite> [<a href="https://doi.org/10.3322/caac.21858" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38990124/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=CA%20Cancer%20J%20Clin&amp;title=Proportion%20and%20number%20of%20cancer%20cases%20and%20deaths%20attributable%20to%20potentially%20modifiable%20risk%20factors%20in%20the%20United%20States,%202019&amp;volume=74&amp;issue=5&amp;publication_year=2024&amp;pages=405-432&amp;pmid=38990124&amp;doi=10.3322/caac.21858&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r59">
<span class="label">59.</span><cite>Viner B, Barberio AM, Haig TR, Friedenreich CM, Brenner DR. The individual and combined effects of alcohol consumption and cigarette smoking on site-specific cancer risk in a prospective cohort of 26,607 adults: results from Alberta’s Tomorrow Project. Cancer Causes Control. 2019;30(12):1313-1326. doi: 10.1007/s10552-019-01226-7
</cite> [<a href="https://doi.org/10.1007/s10552-019-01226-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31535325/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Causes%20Control&amp;title=The%20individual%20and%20combined%20effects%20of%20alcohol%20consumption%20and%20cigarette%20smoking%20on%20site-specific%20cancer%20risk%20in%20a%20prospective%20cohort%20of%2026,607%20adults:%20results%20from%20Alberta%E2%80%99s%20Tomorrow%20Project&amp;volume=30&amp;issue=12&amp;publication_year=2019&amp;pages=1313-1326&amp;pmid=31535325&amp;doi=10.1007/s10552-019-01226-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r60">
<span class="label">60.</span><cite>Falk DE, Yi HY, Hiller-Sturmhöfel S. An epidemiologic analysis of co-occurring alcohol and tobacco use and disorders: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Alcohol Res Health. 2006;29(3):162-171.
</cite> [<a href="/articles/PMC6527037/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17373404/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Alcohol%20Res%20Health&amp;title=An%20epidemiologic%20analysis%20of%20co-occurring%20alcohol%20and%20tobacco%20use%20and%20disorders:%20findings%20from%20the%20National%20Epidemiologic%20Survey%20on%20Alcohol%20and%20Related%20Conditions&amp;volume=29&amp;issue=3&amp;publication_year=2006&amp;pages=162-171&amp;pmid=17373404&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r61">
<span class="label">61.</span><cite>Dawson DA. Drinking as a risk factor for sustained smoking. Drug Alcohol Depend. 2000;59(3):235-249. doi: 10.1016/S0376-8716(99)00130-1
</cite> [<a href="https://doi.org/10.1016/S0376-8716(99)00130-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10812284/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drug%20Alcohol%20Depend&amp;title=Drinking%20as%20a%20risk%20factor%20for%20sustained%20smoking&amp;volume=59&amp;issue=3&amp;publication_year=2000&amp;pages=235-249&amp;pmid=10812284&amp;doi=10.1016/S0376-8716(99)00130-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r62">
<span class="label">62.</span><cite>McKee SA, Weinberger AH. How can we use our knowledge of alcohol-tobacco interactions to reduce alcohol use?
Annu Rev Clin Psychol. 2013;9(1):649-674. doi: 10.1146/annurev-clinpsy-050212-185549
</cite> [<a href="https://doi.org/10.1146/annurev-clinpsy-050212-185549" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3651830/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23157448/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annu%20Rev%20Clin%20Psychol&amp;title=How%20can%20we%20use%20our%20knowledge%20of%20alcohol-tobacco%20interactions%20to%20reduce%20alcohol%20use?&amp;volume=9&amp;issue=1&amp;publication_year=2013&amp;pages=649-674&amp;pmid=23157448&amp;doi=10.1146/annurev-clinpsy-050212-185549&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r63">
<span class="label">63.</span><cite>Roche DJ, Ray LA, Yardley MM, King AC. Current insights into the mechanisms and development of treatments for heavy drinking cigarette smokers. Curr Addict Rep. 2016;3(1):125-137. doi: 10.1007/s40429-016-0081-3
</cite> [<a href="https://doi.org/10.1007/s40429-016-0081-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4859339/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27162709/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Addict%20Rep&amp;title=Current%20insights%20into%20the%20mechanisms%20and%20development%20of%20treatments%20for%20heavy%20drinking%20cigarette%20smokers&amp;volume=3&amp;issue=1&amp;publication_year=2016&amp;pages=125-137&amp;pmid=27162709&amp;doi=10.1007/s40429-016-0081-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r64">
<span class="label">64.</span><cite>King A, Cao D, Vanier C, Wilcox T. Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study. Alcohol Clin Exp Res. 2009;33(6):1044-1050. doi: 10.1111/j.1530-0277.2009.00925.x
</cite> [<a href="https://doi.org/10.1111/j.1530-0277.2009.00925.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4625790/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19302083/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Alcohol%20Clin%20Exp%20Res&amp;title=Naltrexone%20decreases%20heavy%20drinking%20rates%20in%20smoking%20cessation%20treatment:%20an%20exploratory%20study&amp;volume=33&amp;issue=6&amp;publication_year=2009&amp;pages=1044-1050&amp;pmid=19302083&amp;doi=10.1111/j.1530-0277.2009.00925.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r65">
<span class="label">65.</span><cite>Kahler CW, Spillane NS, Metrik J. Alcohol use and initial smoking lapses among heavy drinkers in smoking cessation treatment. Nicotine Tob Res. 2010;12(7):781-785. doi: 10.1093/ntr/ntq083
</cite> [<a href="https://doi.org/10.1093/ntr/ntq083" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2893295/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20507898/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nicotine%20Tob%20Res&amp;title=Alcohol%20use%20and%20initial%20smoking%20lapses%20among%20heavy%20drinkers%20in%20smoking%20cessation%20treatment&amp;volume=12&amp;issue=7&amp;publication_year=2010&amp;pages=781-785&amp;pmid=20507898&amp;doi=10.1093/ntr/ntq083&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="yoi240094r66">
<span class="label">66.</span><cite>Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED. Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. Psychopharmacology (Berl). 2014;231(19):3843-3853. doi: 10.1007/s00213-014-3519-0
</cite> [<a href="https://doi.org/10.1007/s00213-014-3519-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4161630/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24733235/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Psychopharmacology%20(Berl)&amp;title=Varenicline,%20low%20dose%20naltrexone,%20and%20their%20combination%20for%20heavy-drinking%20smokers:%20human%20laboratory%20findings&amp;volume=231&amp;issue=19&amp;publication_year=2014&amp;pages=3843-3853&amp;pmid=24733235&amp;doi=10.1007/s00213-014-3519-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p">
<span>Supplement 1.</span><p>Trial protocol</p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/11822619/bin/jamapsychiatry-e244789-s001.pdf" data-ga-action="click_feat_suppl" class="usa-link">jamapsychiatry-e244789-s001.pdf</a><sup> (6.4MB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="caption p">
<span>Supplement 2.</span><p>eMethods. Supplementary protocol and analysis plan information</p>
<p>eResults. Supplementary results information</p>
<p>eTable 1. Adverse events by medication group and treatment dose/month</p>
<p>eTable 2. Full results for all models examining laboratory self-administration</p>
<p>eTable 3. Full results for linear mixed models examining changes in weekly outcomes</p>
<p>eFigure 1. Duration of delay in laboratory consumption by medication group</p>
<p>eFigure 2. Mean cigarettes per day by week in semaglutide and placebo groups (n = 13)</p>
<p>eFigure 3. Descriptive comparison of drinking outcomes by baseline body mass index (BMI)</p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/11822619/bin/jamapsychiatry-e244789-s002.pdf" data-ga-action="click_feat_suppl" class="usa-link">jamapsychiatry-e244789-s002.pdf</a><sup> (1.3MB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material3_reqid_"><div class="caption p">
<span>Supplement 3.</span><p>Data sharing statement</p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/11822619/bin/jamapsychiatry-e244789-s003.pdf" data-ga-action="click_feat_suppl" class="usa-link">jamapsychiatry-e244789-s003.pdf</a><sup> (12.5KB, pdf) </sup>
</div></div></section></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from JAMA Psychiatry are provided here courtesy of <strong>American Medical Association</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1001/jamapsychiatry.2024.4789"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/11822619/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/11822619/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11822619%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11822619/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC11822619/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC11822619/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/39937469/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC11822619/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/39937469/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC11822619/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/11822619/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="vq8p8CNLMpDTkP0zgqr718DWgIbShi1qlh1FrEBWwgMnj87BzYMLX0w8An7EGhlX">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-B7-tgZZA.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-BLbQGH8u.js"></script>
    
    

    </body>
</html>
